Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1268464 10.3389/fphar.2024.1268464 Pharmacology Review Scopoletin: a review of its pharmacology, pharmacokinetics, and toxicity Gao et al. 10.3389/fphar.2024.1268464 Gao Xiao-Yan 1 2 3 Li Xu-Yang 1 2 Zhang Cong-Ying 1 2 3 Bai Chun-Ying 1 2 * 1 Basic Medicine College, Chifeng University, Chifeng, China 2 Inner Mongolia Key Laboratory of Human Genetic Disease Research, Chifeng University, Chifeng, China 3 Key Laboratory of Mechanism and Evaluation of Chinese and Mongolian Pharmacy at Chifeng University, Chifeng University, Chifeng, China

Edited by: Hafiz A. R. Suleria, The University of Melbourne, Australia

Reviewed by: Yongqiang Zhang, Southwest University, China

Aram Megighian, University of Padua, Italy

 *Correspondence: Chun-Ying Bai, cfxybcy@163.com 23 02 2024 2024 15 1268464 28 07 2023 24 01 2024 Copyright © 2024 Gao, Li, Zhang and Bai. 2024 Gao, Li, Zhang and Bai

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Scopoletin is a coumarin synthesized by diverse medicinal and edible plants, which plays a vital role as a therapeutic and chemopreventive agent in the treatment of a variety of diseases. In this review, an overview of the pharmacology, pharmacokinetics, and toxicity of scopoletin is provided. In addition, the prospects and outlook for future studies are appraised. Scopoletin is indicated to have antimicrobial, anticancer, anti-inflammation, anti-angiogenesis, anti-oxidation, antidiabetic, antihypertensive, hepatoprotective, and neuroprotective properties and immunomodulatory effects in both in vitro and in vivo experimental trials. In addition, it is an inhibitor of various enzymes, including choline acetyltransferase, acetylcholinesterase, and monoamine oxidase. Pharmacokinetic studies have demonstrated the low bioavailability, rapid absorption, and extensive metabolism of scopoletin. These properties may be associated with its poor solubility in aqueous media. In addition, toxicity research indicates the non-toxicity of scopoletin to most cell types tested to date, suggesting that scopoletin will neither induce treatment-associated mortality nor abnormal performance with the test dose. Considering its favorable pharmacological activities, scopoletin has the potential to act as a drug candidate in the treatment of cancer, liver disease, diabetes, neurodegenerative disease, and mental disorders. In view of its merits and limitations, scopoletin is a suitable lead compound for the development of new, efficient, and low-toxicity derivatives. Additional studies are needed to explore its molecular mechanisms and targets, verify its toxicity, and promote its oral bioavailability.

 scopoletin plant sources pharmacological activities pharmacokinetics toxicology section-at-acceptance Ethnopharmacology 1 Introduction

In recent years, functional components of food sources have aroused considerable interest because of their benefits in preventing illnesses and promoting health (Iahtisham Ul et al., 2019). Scopoletin (6-methoxy-7-hydroxycoumarin, Figure 1) is a phenolic coumarin that is extracted from numerous medicinal and edible plants and has various pharmacological activities. Scopoletin is synthesized by diverse medicinal plants, such as Erycibe obtusifolia (Pan et al., 2011a), Aster tataricus (Ng et al., 2003), Foeniculum vulgare (Kwon et al., 2002), Artemisia annua (Tzeng et al., 2007), Sinomenium acutum (Shaw et al., 2003), Melia azedarach (Carpinella et al., 2005), and Artemisia iwayomogi, as well as certain edible plants, such as Lycium barbarum and Morinda citrifolia (Dou et al., 2013; Lee et al., 2014; Forino et al., 2016; Mohamad Shalan et al., 2016). In addition, it is a component of numerous fruit and vegetable crop plants, including Avena sativa, Allium ampeloprasum, Apium graveolens, Capsicum annuum, Capsicum frutescens, Daucus carota, Cichorium intybus, Citrus limon, and Citrus aurantium, demonstrating its low toxicity as well as its safe application as a synergistic compound together with synthetic or other natural substances, such as vanillin (Carpinella et al., 2005).

Structure of scopoletin.

Scopoletin has attracted the attention of medicinal chemists and health professionals because of its broad range of beneficial properties, such as antibacterial, antifungal, antiparasitic, anticancer, anti-inflammation, hepatoprotective, antihyperlipidemic, antidiabetic, neuroprotective, antioxidant, anti-angiogenesis, anti-hypertensive, analgesic, anxiolytic, immunomodulatory, anti-osteoporosis, anti-allergic, anti-aging, and anti-gout activities. In addition, scopoletin is an inhibitor of various enzymes, including choline acetyltransferase, acetylcholinesterase inhibitor (Rollinger et al., 2004; Hornick et al., 2011), aldose reductase (Lee et al., 2010), γ-aminotransferase (half-maximal inhibitory concentration [IC50] = 10.57 μM) (Mishra et al., 2010), monoamine oxidase (Yun et al., 2001), quinone oxidoreductase (Khunluck et al., 2019), and inducible nitric oxide synthase (iNOS) (Kim et al., 1999).

Scopoletin is a hydroxycoumarin with a molecular weight of 192.7 g/mol and a melting point of 204°C–206°C. The empirical formula of the compound is C10H8O4. It is slightly soluble in water or cold ethanol, soluble in hot ethanol or hot acetic acid, easily soluble in chloroform, and almost insoluble in benzene. Scopoletin is biosynthesized by ortho-hydroxylation of feruloyl-CoA in Arabidopsis thaliana (Figure 2) (Kai et al., 2008). Scopoletin is widely distributed in medicinal plants of various families and genera, including Malva (Lagunas-Herrera et al., 2019; Medrano-Jiménez et al., 2019), Cynodon (Patel et al., 2013), Convolvulus (Kaur et al., 2016; Garg et al., 2018), Artemisia (Kang et al., 1999; Choi et al., 2012; Kim et al., 2018), Erycibe (Pan et al., 2010), Canarium (Mogana et al., 2013), and Brunfelsia (Oliveira et al., 2001). It is also present in the whole plant of Viola mandshurica W. Becker (Park et al., 2017), Polygala sabulosa A.W. Bennett (Meotti et al., 2006; Ribas et al., 2008; Capra et al., 2010; Pereira Dos Santos Nascimento et al., 2016), Hedyotis diffusa Willd. (Chen et al., 2018), and Artemisia annua L. (Seo et al., 2016); in the aerial parts of Artemisia capillaris Thunb. (Navarro-García et al., 2011), Mitracarpus frigidus Willd. (Lemos et al., 2020), Solanum lyratum Thunb. (Kang et al., 1998), and Cirsium setidens (Dunn) Nakai (Ahn et al., 2014); in the roots of Hibiscus syriacus L. (Yun et al., 2001), Urtica dioica L. (Nahata and Dixit, 2012), Biebersteinia multifida DC. (Monsef-Esfahani et al., 2013), Gelsemium sempervirens L. (Khuda-Bukhsh et al., 2010), Saposhnikovia divaricata Turcz. Schischk (Kamino et al., 2016), Hypochaeris radicata L. (Jamuna et al., 2015), Argyreia speciosa L.f. (Kashyap et al., 2020), and Angelica pubescens Maxim. (Yang et al., 2009); the fruit of Tetrapleura tetraptera (Schumach. and Thonn.) Taub (Ojewole and Adesina, 1983); the flowers of Tilia cordata Mill. (Barreiro Arcos et al., 2006), the heartwood of Acer nikoense Miq. (Iizuka et al., 2007); and the inner shell of the nut of Castanea crenata (Noh et al., 2010). In addition, scopoletin has been analyzed in Morinda citrifolia L. (Kishore Kumar et al., 2017; Wigati et al., 2017; Ahmadi et al., 2019), Fraxinus rhynchophylla Hance (Kim et al., 1999), Torilis radiata (Ezzat et al., 2012), Brunfelsia hopeana Benth. (Oliveira et al., 2001), and Canarium patentinervium Miq. (Mogana et al., 2013). Table 1 summarizes the main plant sources of scopoletin and the associated bioactivities.

Synthesis of scopoletin (Kai et al., 2008).

Main plant sources of scopoletin and their bioactivities.

Family Species Parts of plant Content W/W (%) Bioactivity Reference
Malvaceae Malva parviflora L. Whole plant Not measured Anti-hypertension and anti-AD Lagunas-Herrera et al. (2019), Medrano-Jiménez et al. (2019)
Poaceae Cynodon dactylon Linn. Whole plant Not measured Anti-asthma Patel et al. (2013)
Convolvulaceae Convolvulus pluricaulis Chois. Whole plant Not measured Anti-oxidant and anti-hyperlipidemia Kaur et al. (2016), Garg et al. (2018)
Violaceae Viola mandshurica W.Becker Whole plant Not measured Anti-atherosclerosis Park et al. (2017)
Rubiaceae Hedyotis diffusa Willd. Whole plant 0.0528 Chen et al. (2018)
Polygalaceae Polygala sabulosa A.W. Bennett Whole plant 0.0287, 0.112 Anti-pleurisy, anti-depression, and antinociceptive Meotti et al. (2006); Ribas et al. (2008); Capra et al. (2010); Pereira Dos Santos Nascimento et al. (2016)
Compositae Artemisia annua Linn. Whole plant Not measured Anti-cancer Seo et al. (2016)
Apiaceae Torilis radiata Moench. Aerial parts 0.0045 Hepatoprotective Ezzat et al. (2012)
Compositae Artemisia capillaris Thunb. Aerial parts Not measured Downregulated MMP-1 and suppressed primary splenocyte proliferation Kim et al. (2018); Lee et al. (2017)
Rubiaceae Mitracarpus frigidus Willd. Aerial parts 23.07 (scopoletin/extract) Antifungal Lemos et al. (2020)
Polemoniaceae Loeselia mexicana Lamb. Aerial parts 0.005 Antifungal Navarro-García et al. (2011)
Solanaceae Solanum lyratum Thunb. Aerial parts 0.00023 Hepatoprotective activity (Kang et al., 1998)
Compositae Cirsium setidens Nakai. Aerial parts Not measured Increased melanin synthesis Ahn et al. (2014)
Compositae Artemisia feddei Lev. Aerial parts 0.024 Inhibited NO Kang et al. (1999)
Asteraceae Artemisia iwayomogi Kitam. Leaves and stems Not measured Anti-inflammatory Choi et al. (2012)
Convolvulaceae Erycibe obtusifolia Benth. Stems 0.022 Anti-angiogenesis and anti-arthritic Pan et al. (2010)
Solanaceae Nicotiana glauca Graham. Leaves Not measured Anti-tumor Tabana et al. (2016)
Rutaceae Melicope lunuankenda Leaves Not measured Inhibited α-glucosidase activity Al-Zuaidy et al. (2016)
Rutaceae Aegle marmelos Linn. Leaves Not measured Decreased serum glucose Panda and Kar (2006)
Solanaceae Nicotiana glauca Graham. Leaves Not measured Anti-tumor Tabana et al. (2016)
Burseraceae Kunth Canarium patentinervium Miq. Leaves and barks 0.98 Anti-inflammatory, anti-cholinesterase, and anti-oxidant Mogana et al. (2013)
Solanaceae Nicotiana glauca Graham. Leaves Not measured Anti-tumor Tabana et al. (2016)
Convolvulaceae Erycibe schmidtii Craib. Twigs and leaves 0.066 Anti-rheumatoid arthritis Ren et al. (2020)
Rubiaceae Morinda citrifolia L. Fruits and leaves 0.46 ± 0.05 (leaf) Antioxidant, anti-inflammatory, anti-leukemia, anti-hypertension, anti-PD, antibacterial, anti-angiogenic, anti-gastric ulcer, gastrokinetic activity, and anti-dyslipidemic Mandukhail et al. (2010); Mahattanadul et al. (2011); Beh et al. (2012); Nima et al. (2012); Mohamad Shalan et al. (2016); Kishore Kumar et al. (2017); Wigati et al. (2017); Ahmadi et al. (2019); De La Cruz-Sánchez et al. (2019); Narasimhan et al. (2019)
Rubiaceae Morinda citrifolia L. Fruits 0.06 Parkinson’s disease Kishore Kumar et al. (2017)
Mimosaceae Tetrapleura tetraptera (Taub) Fruits Not measured Spasmolytic activity Ojewole and Adesina (1983)
Malvaceae Hibiscus syriacus Linn. Root bark 0.0021 Anti-oxidative Yun et al. (2001)
Urticaceae Stinging nettle (Urtica dioica L.) Roots Not measured Benign prostatic hyperplasia Nahata and Dixit (2012)
Solanaceae Brunfelsia hopeana Benth. Roots 0.01125 Anti-hypertension Oliveira et al. (2001)
Geraniaceae Biebersteinia multifida DC. Roots Not measured Anxiolytic effects Monsef-Esfahani et al. (2013)
Loganiaceae Gelsemium sempervirens L. Roots and rhizomes Not measured Anticancer Khuda-Bukhsh et al. (2010)
Umbelliferae Saposhnikovia divaricata Turcz. Roots and rhizomes 0.0039 Inhibited NO Kamino et al. (2016)
Asteraceae Hypochaeris radicata Var. Roots Not measured Anti-inflammatory Jamuna et al. (2015)
Convolvulaceae Argyreia speciosa Linn. Roots 0.56% (scopoletin/extract) Anti-amyloidogenic Kashyap et al. (2020)
Umbelliferae Angelicae Pubescentis Maxim. Root 0.0001 Yang et al. (2009)
Fagaceae Castanea crenata Inner shells Not measured Anti-oxidant Noh et al. (2010)
Aceraceae Acer nikoense Miq. Heartwood Not measured Vasorelaxant Iizuka et al. (2007)
Tiliaceae Tilia cordata Mill. Flowers Not measured Anti-tumor Barreiro Arcos et al. (2006)
Oleaceae Fraxinus rhynchophylla Hance. Barks 0.0025 Inhibited NO Kim et al. (1999)

The present review concentrates on recent research progress associated with the role of scopoletin in the prevention and/or treatment of illnesses and disorders, stressing the mechanism of its action and discussion of its toxicity and pharmacokinetic characteristics. Accordingly, recent literature concerning the bioactivity and uses of scopoletin as a chemotherapeutic agent was collated from multiple databases.

 2 Pharmacological activities of scopoletin

A considerable body of evidence has proven the benefits of scopoletin in human health (Figure 3). Table 2 summarizes the health-promoting activities of scopoletin and the underlying mechanism of action for various illnesses and disorders. Details concerning the activity of scopoletin against various illnesses and disorders are discussed in the following sections.

Main biological activities and possible molecular mechanisms of scopoletin.

Treatment perspectives of scopoletin.

Disorder Mechanism Reference
Antifungal Cell wall and membrane damage ↑, apoptosis ↑, oxidative imbalance ↑, and metabolic activities ↓ Das et al. (2020a); Lemos et al. (2020)
Antibacterial Bacterial cell division ↓ Duggirala et al. (2014)
Cancer Cell proliferative ↓ Barreiro Arcos et al. (2006); Manuele et al. (2006)
Cell cycle arrest ↑, apoptosis ↑, and caspase-3 ↑ Liu et al. (2001)
Caspase-3 ↑ and NF-κB ↑ Kim et al. (2005)
Caspase-3 ↑, caspase-8 ↑, bone marrow myeloblast levels ↓, CSF3 ↓, SOCS1 ↓, PTEN ↓, TRP53 ↓, VEGF↓, IL-10 ↑, and IL-4 ↑ Ahmadi et al. (2019)
Cyclin-D1↓, PCNA ↓, STAT-3 ↓, P53 ↑, and caspase-3 ↑ Khuda-Bukhsh et al. (2010); Bhattacharyya et al. (2011)
Cell cycle arrest ↑ and apoptosis ↑ Asgar et al. (2015)
NQO1↓ and cell migration ↓ Khunluck et al. (2019)
Cell cycle arrest ↑, cleaved-3/8/9 ↑, PARP ↑, cell invasion ↓, p-PI3K ↓, and p-AKT ↓ Tian et al. (2019)
Tumor growth ↓, vascularization ↓, and anti-vascular effect ↑ Tabana et al. (2016)
NF-κB ↓ Seo et al. (2016)
Arthritis Synovial angiogenesis ↓ and apoptosis ↑ Ying et al. (2009); Pan et al. (2010); Pan et al. (2011a)
IL-6 ↓, cell proliferation ↓, MAPKs ↓, PKC ↓, and CREB ↓ Dou et al. (2013)
COX-2 ↓ Chen et al. (2021)
Cell proliferation ↓ Ren et al. (2020)
IL-β ↓, TNF-α ↓, H2S ↓, chemoattractant protein 1↓, IL-33 ↓, preprotachykinin A ↓, and NF-κB ↓ Leema and Tamizhselvi (2018)
Pleurisy NF-κB ↓ and MAPKs ↓ Pereira Dos Santos Nascimento et al. (2016)
Asthma K+ ↓ and Ca2+ ↓ Patel et al. (2013)
Autoimmune encephalomyelitis NF-κB ↓, demyelination ↓, MHC class II ↓, CD80 ↓, and CD86↓ Zhang et al. (2019)
Acute liver injury ALT ↑, AST ↑, LDH ↑, TNF-α ↓, NO ↓, NAG ↓, MPO ↓, MDA ↓, CAT ↑, and GSH ↑ Ezzat et al. (2012)
GSH ↑, SOD ↑, and MDA ↓ Kang et al. (1998)
ROS ↓, CAT ↑, SOD ↑, GPx ↑, and MDA ↓ Noh et al. (2010)
Alcoholic liver AMPK ↑, ACC ↓, SREBP-1c ↓, FAS ↓, PAP ↓, G6PD ↓, CYP2E1 ↓, SOD ↑, CAT ↑, GSH-Px ↑, GST ↑, and GSH ↑ Lee et al. (2014)
TG ↓, adiponectin↑, AMPK ↑, SREBP-1c ↓, FAS ↓, PPARα ↑, ACSL1 ↑, CPT ↑, ACOX ↑, ACAA1A ↑, TLR4 ↓, MyD88 ↓, TRIF ↓, NF-κB ↓, TNF-α ↓, and IL-6 ↓ Lee and Lee (2015a)
Glucose intolerance ↓, HOMA-IR ↓, serum insulin level ↓, IR ↓, PI3K ↑, GK ↑, G6Pase ↓, SOD ↑, CAT ↑, GPx ↑, H2O2 ↓, and MDA ↓ Lee and Lee (2015b)
ALT ↓, AST ↓, TG ↓, TBARS ↓, CAT ↑, SOD ↑, GPx ↑, GR ↑, and CYP2E1 ↓ Noh et al. (2011)
Non-alcoholic fatty liver Body weight ↓, visceral fat ↓, leptin ↓, TG ↓, TC ↓, TNF-α ↓, IL-6 ↓, IFNγ ↓, MCP-1 ↓, serum glucose ↓, insulin ↓, HOMA-IR ↓, IPGTT ↓, ERRFI1 ↑, APOA4 ↓, CYP7A1 ↓, COL1A1 ↓, MMP-13 ↓, CDKN1A ↓, and GDF-15 ↓ Ham et al. (2016)
Body/liver weight ↓, TG ↓, TC ↓, LDL ↓, glucose ↓, ALT ↓, AST ↓, ACC ↓, SREBP-1c ↓, and p-AMPK ↑ Park et al. (2017)
Hyperlipidemia TG ↓ and TC ↓ Kim et al. (2017a)
TG ↓, TC ↓, and glucose ↓ Mandukhail et al. (2010)
TG ↓, TC ↓, LDL ↓, and MDA ↓ Garg et al. (2018)
Diabetic α-glucosidase ↓, α-amylase ↓, and postprandial hyperglycemia ↓ Abdullah et al. (2016); Jang et al. (2018)
α-glucosidase ↓, DPPH radical activity↓, and fasting blood glucose ↓ Al-Zuaidy et al. (2016)
Glucose uptake ↑, GLUT4 ↑, p-Akt ↑, PI3K ↑, and AMPK ↑ Jang et al. (2020)
PPARγ 2 ↑, IR ↓, p-Akt ↑, and p-PKB ↑ Zhang et al. (2010)
Serum glucose ↓ and G6PD ↓ Panda and Kar (2006)
Insulin secretion ↑, blood glucose ↓, TG ↓, and TC ↓ Verma et al. (2013)
HbA1 ↓, blood glucose ↓, FFA ↓, TG ↓, TC ↓, ALT ↓, TLR4 ↓, MyD88 ↓, TNF-α ↓, IL-6 ↓, PPARγ ↓, DGAT2 ↓, and MCP-1 ↓ Choi et al. (2017)
AGEs ↓, TG ↓, TC ↓, LDL ↓, HDL ↑, D-lactic acid ↑, IR ↓, blood glucose ↓, Nrf2 ↑, PPARγ ↑, p-AKT ↑, PTP1B ↓, and GLUT2 ↑ Chang et al. (2015)
AMPK ↑, IRS1 ↑, PI3K ↑, Akt ↑, TBARS ↓, LHP ↓, PC ↓, SOD ↑, GPX ↑, CAT ↑, HOMA-IR ↓, TC ↓, TG ↓, HDL-C ↑, LDL ↓, and VLDL ↓ Kalpana et al. (2019)
AGE formation ↓ and RLAR ↓ Lee et al. (2010)
AR ↓, oxidative stress ↓, galactitol ↑, and GSH ↑ Kim et al. (2013)
Alzheimer’s Aβ42 fibril ↓, AChE ↓, BuChE ↓, oxidative stress ↓, and neurotoxicity ↓ Kashyap et al. (2020)
AChE ↑, LTP ↑, LTD ↓, and memory retention ↑ Hornick et al. (2011); Das et al. (2020a)
Microglia phagocytic ↑, PPARγ ↑, CD36 ↑, TNF-α ↓, IL-6 ↓, and amyloid plaque ↓ Medrano-Jiménez et al. (2019)
Apoptotic ↓, ROS ↓, SIRT1 ↑, FOXO3A ↑, ADAM10 ↑, Bcl2 ↑, CAT ↑, and SOD ↑ Gay et al. (2020)
Parkinsonism SOD ↑, CAT ↑, GST ↑, Nrf2 ↑, GR ↑, ARE ↑, DJ-1 ↑, Keap1 ↓, and GUL3 ↑ Narasimhan et al. (2019)
Cell death ↓, striatal neuronal loss ↑, Bax ↓, Bcl2 ↑, and cytochrome C ↓ Kishore Kumar et al. (2017)
GSH ↑, redox balance ↑, mitochondrial function ↑, and oxidative damage ↓ Pradhan et al. (2020)
Huntington’s disease Body weight ↑, locomotor activity ↑, grip strength ↑, gait abnormalities ↑, MDA ↓, nitrite ↓, SOD ↑, and GSH ↑ Kaur et al. (2016)
Spinal cord injury AMPK ↑, mTOR ↑, motor neuronal ↑, apoptosis ↓, autophagy ↑, beclin-1 ↑, and LC3B-positive neuronal cells ↑ Zhou et al. (2020)
Anxiety MAOs ↓ Monsef-Esfahani et al. (2013)
Microglia activation ↓, IL-1β ↓, IL-6 ↓, TNF-α ↓, MAPK ↓, NF-κB ↓, and GABA-T ↓ Luo et al. (2020)
Schizophrenia Climbing behavior ↓ and stereotyped behavior ↓ Pandy and Vijeepallam (2017)
Depressant Depression-like behavior ↓ and immobility time ↓ Capra et al. (2010)
Antioxidant Superoxide anion ↓, SOD ↑, CAT ↑, and GSH ↑ Shaw et al. (2003)
LDL oxidation ↓ and TBARS ↓ Thuong et al. (2005)
Anti-angiogenesis Branching pattern of blood vessels ↓ Beh et al. (2012)
Blood vessels ↓, tube formation ↓, proliferation ↓, and migration ↓ Pan et al. (2011b)
VEGFR2↓, proliferation ↓, migration ↓, tube formation ↓, and ERK1/2 ↓ Pan et al. (2009)
Hypertension Relaxed smooth muscles ↑, spasmogenic activities ↓, ACE ↓, and portal vein contractions ↓ Ojewole and Adesina (1983)
Contractile responses ↓ Iizuka et al. (2007)
SBP ↓, DBP ↓, TNF-α ↓, MDA ↓, IL-6 ↓, and IL-1β ↓ Lagunas-Herrera et al. (2019)
SBP ↓ and DBP ↓ Wigati et al. (2017)
Anti-gout Uric acid ↓ Ding et al. (2005)
Allergic PMA ↓, IL-4 ↓, IL-5 ↓, IL-10 ↓, IFN-γ ↑, NFAT↓, GATA-3 ↓ Cheng et al. (2012)
Vitiligo MITF ↑, tyrosinase ↑, p-CREB↑, cAMP/PKA ↑, and P38MAPK ↑ Ahn et al. (2014); Kim et al. (2017b); Heriniaina et al. (2018)
Antiaging MMP-1↓, IL-1α ↓, TNF-α ↓, and p-P38 ↓ Kim et al. (2018)
SA-β-Gal staining ↓, HDAC1↑, SIRT1 ↑, SIRT6↑, Nrf-2 ↑, p-FoxO1↑, and P53 ↑ Nam and Kim (2015)
Anticonvulsant GABA transaminase ↓ Mishra et al. (2010)
Immunomodulatory Macrophage phagocytic activity ↑ Mankar et al. (2013)
Macrophage phagocytic activity ↑ and phagocytosis-linked genes (CDC42 ↓, FCGR1A ↓, FCGR1C ↓, ITGA9 ↓, ITGB3 ↓, PLCE1 ↓, RHOD ↓, RND3 ↓, DIRAS3 ↑, ITGA1 ↑, PIK3CA ↑, PIK3R3↑, and PLCD1↑) Alkorashy et al. (2020)
Splenocyte proliferation ↓ and adaptive immune cell activation ↓ Lee et al. (2017)
Osteoporosis Osteoclastic differentiation ↓, ROS ↓, superoxide anion ↓, NF-κB ↓, and peroxyl radical-scavenging ↑ Lee et al. (2013)
Analgesic Glutamatergic transmission ↓, TNF-α ↓, and IL-1β ↓ Ribas et al. (2008)

↓, downregulation, inactivation, and inhibition; ↑, upregulation and activation.

 2.1 Anti-microbial activities 2.1.1 Antifungal activity

The microbial population, inside and outside the human body, plays a vital role in human health because many microbes may induce illnesses. Scopoletin shows maximum antifungal activity against Trichophyton mentagrophytes, Aspergillus niger, and Candida albicans (Navarro-García et al., 2011). The minimum inhibitory concentration (MIC) of scopoletin against Candida glabrata and Candida tropicalis is 67.22 and 119 μg/mL, respectively, which initiates an oxidative imbalance and reduces metabolism to achieve its antibacterial effect on these two Candida species (Das et al., 2020). Scopoletin has antifungal properties effective against a multidrug-resistant strain of C. tropicalis. Its mechanism of action is interference in the synthesis of essential fungal cell components, disruption of cell walls and plasma membranes, and impairment of C. tropicalis biofilm growth, formation, and proliferation (Lemos et al., 2020). Recent studies have reported that scopoletin has strong antitubercular activity; the compound isolated from Morinda citrifolia roots exhibits high activity against Mycobacterium tuberculosis with an MIC of 50 μg/mL (Sam-Ang et al., 2023). The MIC of the crude ethanol extract from the stem bark of Hymenodictyon floribundum BL Rob. against Mycobacterium indicum and Mycobacterium madagascariense is 195 and 781.25 μg/mL, respectively (Marealle et al., 2023).

 2.1.2 Antibacterial activity

Several studies have reported that scopoletin is active against Staphylococcus aureus (Buathong et al., 2019; De La Cruz-Sánchez et al., 2019; Ramírez-Reyes et al., 2019; Chandrasekhar et al., 2023). Scopoletin exerts antimycobacterial activity against Streptococcus pyogenes, Pseudomonas aeruginosa, P. aeruginosa DMSC 37166, Mycobacterium tuberculosis H37Rv, Actinomyces israelii, Actinomyces naeslundii, and Salmonella typhi (Chiang et al., 2010; More et al., 2012; Acharya et al., 2013; Meerungrueang and Panichayupakaranant, 2014; Napiroon et al., 2018). In addition, Duggirala et al. reported that scopoletin inhibited both the polymerization and GTPase activity of filamentous temperature-sensitive protein Z, a target of anti-bacterial drugs, so it may be used as a lead structure for anti-filamentous temperature-sensitive protein Z drug design (Duggirala et al., 2014). Molokoane et al. reported that the compound from Artemisia afra (62.5 μg/mL) showed good activity against Escherichia coli (Molokoane et al., 2023).

 2.1.3 Antiparasitic activity

Scopoletin significantly inhibits the growth of Plasmodium yoelii and Trypanosoma brucei brucei (Mamoon Ur et al., 2014; Li et al., 2018).

 2.1.4 Antiviral activity

Individual fractions of scopoletin isolated from Artemisia annua exert strong virucidal and antiviral effects at a minimum concentration of 50 μg/mL in vitro and have been shown to inhibit SARS-CoV-2 infection (Baggieri et al., 2023).

 2.2 Anticancer activity

The antitumor activity of scopoletin may result from its anti-proliferation, anti-migration, pro-apoptotic, anti-invasion, and anti-angiogenic inhibition of multiple drug resistance, regulation of the mitogen-activated protein kinase (MAPK) and PI3K/AKT/mTOR pathways, and its effect on cell cycle arrest (Antika et al., 2023).

Scopoletin shows anti-proliferative action on BW5147 murine lymphoma cells and MCF-7 human adenocarcinoma cells (Barreiro Arcos et al., 2006; Manuele et al., 2006; Nasseri et al., 2022). It exerts anticancer effects on human cervical cancer cell lines by inducing apoptosis and cell cycle arrest and inhibiting cell invasion and the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway (Tian et al., 2019). It is indicated to play a role in triggering cell cycle arrest and increasing apoptosis in PC3 cells via activation of caspase-3 (Liu et al., 2001). Scopoletin has been reported to activate nuclear factor-kappa B (NF-κB), caspase-3, and PARP cleavage, leading to apoptosis of promyeloleukemic HL-60 cells (Kim et al., 2005). Scopoletin causes human melanoma cell A375 apoptosis through downregulation of cyclin-D1; proliferation of cell nuclear antigen, survivin, and Stat-3; and upregulation of p53 and caspase-3 (Khuda-Bukhsh et al., 2010). Similar outcomes have been observed for cholangiocarcinoma cells and cervical cancer cells with respect to cell cycle arrest (G0/G1) and apoptosis induction, and an increase in cytotoxicity by co-administration of cisplatin and scopoletin is indicated (Asgar et al., 2015). Scopoletin has a significant inhibitory effect on A549 cells, with an IC50 of approximately 16 μg/mL (Yuan et al., 2021). In human Jurkat leukemia cells and leukemia-induced BALB/c mice, scopoletin shows anti-leukemia activity associated with cancer cell apoptosis and inhibition of inflammation and angiogenesis and mitigation of bone marrow myeloblast imbalance (Ahmadi et al., 2019). Angiogenesis plays an important role in tumor growth and metastasis (Yamakawa et al., 2018). Beh et al. observed that scopoletin (10, 30, and 100 nmol/egg) decreases the number of vascular branch points in a dose-dependent manner in chick embryo chorioallantoic membranes (Beh et al., 2012). Tabana et al. concluded that scopoletin (100 and 200 mg/kg, p.o.) shows anti-tumorigenic and anti-angiogenic activity in a nude mouse xenograft model by inhibiting vascular endothelial growth factor A (VEGFA), fibroblast growth factor 2 (FGF2), and extracellular signal-regulated kinase-1 (ERK-1) (Tabana et al., 2016). Scopoletin inhibits in vitro tube formation, proliferation, and migration in human umbilical vein endothelial cells and functions by obstructing VEGFR2 autophosphorylation and inhibiting ERK1/2, p38 MAPK, and Akt activation (Pan et al., 2009; Pan et al., 2011b; Cai et al., 2013). Scopoletin exposure upregulates cell cycle arrest in cancer cells, including cervical (Tian et al., 2019), cholangiocarcinoma (Prompipak et al., 2021), breast cancer (Yu et al., 2021), hepatoma, and lung cancer cells (Shi et al., 2020). A recent study has reported that matrine and scopoletin are effective ingredients of the Qinghao–Kushen combination combating liver cancer, which reduce the expression of GSK-3β in HepG2 cells and upregulate GSK-3β in HepG2.2.15 cells (Ji et al., 2022).

 2.3 Anti-inflammatory activity

Administration of scopoletin inhibits mouse ear edema induced by ethyl phenylpropiolate, 12-O-tetradecanoylphorbol-13-acetate, croton oil, carrageenan, and 2,4-dinitrochlorobenzene, as well as paw and skin inflammation (Farah and Samuelsson, 1992; Muschietti et al., 2001; Ding et al., 2008; Selim and Ouf, 2012; Jamuna et al., 2015; Bak et al., 2022), which may be associated with modulation of the generation of pro-inflammatory mediators, tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), prostaglandin E2, and IL-6, which suppresses cyclooxygenase-2 (COX-2) and iNOS expression. In lipopolysaccharide (LPS)-stimulated human gingival fibroblast and RAW 264.7 cells, scopoletin significantly inhibits the expression levels of the pro-inflammatory mediators IL-6 and TNF-α, thus prohibiting COX-2, iNOS, and nitric oxide (NO) expression (Kim et al., 1999; Kim et al., 2004; Choi et al., 2012; Kamino et al., 2016; Chaingam et al., 2021). However, the mechanism by which scopoletin influences the generation of inflammatory cytokines remains unclear. Moon et al. revealed that scopoletin (0.01–0.2 mM) suppresses the generation of inflammatory cytokines induced by phorbol 12-myristate 13-acetate plus A23187 by suppressing IκBα phosphorylation and degradation to obstruct NF-κB activation (Moon et al., 2007). In vitro assays indicate that scopoletin (100 and 200 mg/kg, i.p.) suppresses monosodium urate crystal-induced leukocyte infiltration and activation by inhibiting the synthesis and release of inflammatory mediators of activated macrophages. Scopoletin may exert anti-inflammatory effects through prevention of NF-κB signaling and the MAPK pathway (Yao et al., 2012). Pereira et al. reported that the anti-pleurisy effect of scopoletin is mainly mediated by inhibition of pro-inflammatory cytokines (TNF-α and IL-1β), NF-κB, and p38 MAPKs (Pereira Dos Santos Nascimento et al., 2016) and reduction in central nervous system inflammation via suppression of NF-κB signaling (Zhang et al., 2019). In addition, the regulation of the NF-κB signaling pathway reduces airway inflammation in platelet-derived growth factor BB-induced airway smooth muscle cells (Fan et al., 2022). In addition, a scopoletin-rich Morinda citrifolia leaf extract reduces TNF-α, IL-1β, and NO levels in serum, which relieves osteoarthritis symptoms (Wan Osman et al., 2019).

2.3.1 Anti-dendritic cell activity

Rheumatoid arthritis is an autoimmune disorder characterized by synovial hyperplasia and inflammation as well as resulting in joint destruction and deformity (Sajti et al., 2004). The synovium relies on blood supply for proliferation and formation of a pannus that invades the cartilage and bone, causing osteoclast activation and cartilage and bone destruction (Kimura et al., 2007). Dendritic cells are bone marrow-derived cells that arise from lymphoid–bone marrow hematopoiesis and coordinate innate and adaptive immune responses (Collin and Ginhoux, 2019). Immature dendritic cells are preferentially localized at the lining or sub-lining layer of the rheumatoid arthritis synovium (Page et al., 2002). Scopoletin (1 and 5 μM) functionally decreases the proliferation of bone marrow immature dendritic cells (Ren et al., 2020). Scopoletin (50 and 100 mg/kg), in part, improves the clinical state of rat adjuvant-induced arthritis through ameliorating synovial inflammation and destruction of cartilage and bone, thus blocking synovial angiogenesis, triggering apoptosis of fibroblast-like synoviocytes, and inhibiting COX-2 (Ying et al., 2009; Pan et al., 2010; Chen et al., 2021; Gao et al., 2011). The anti-rheumatoid arthritis activity of scopoletin (15, 30, and 60 μM) is likely exerted by suppression of IL-6 generation by fibroblast-like synoviocytes of adjuvant arthritis and potential activation of the MAPK/protein kinase C/cAMP response element-binding protein (CREB) (Dou et al., 2013). Furthermore, scopoletin (30, 40, and 50 μM) inhibits fibroblast-like synovial cells and blocks NF-κB signal transduction, thus combating rheumatoid arthritis (Chen et al., 2022). In addition, scopoletin isolated from Bouvardia ternifolia (Cav.) Schltdl. inhibits NF-κB expression, thereby exerting its anti-rheumatoid arthritis action in Freund’s complete adjuvant-induced ICR mice (Zapata Lopera et al., 2022).

 2.4 Effects of scopoletin on liver diseases

The common clinical liver diseases are mainly viral diseases caused by hepatitis B and C viral infection, drug-induced liver injury, alcoholic fatty liver disease, non-alcoholic fatty liver disease (NAFLD), cirrhosis, and liver cancer.

2.4.1 Acute liver injury

Acute liver injury is the beginning of the progression of many liver diseases leading to liver failure; hence, it is a crucial research focus. Models to simulate acute liver injury mainly include a chemical liver injury model induced by carbon tetrachloride (CCl4), drug-induced liver injury model, drug liver injury model induced by lipopolysaccharide, and alcohol-induced alcoholic liver injury model.

Scopoletin (1, 5, and 10 mg/kg) reduces the activity of an antioxidant enzyme (superoxide dismutase, SOD) and reduced glutathione (GSH) content, inhibits the production of malondialdehyde (MDA), and resists oxidative stress during acute liver injury induced by CCl4 in rats so as to protect the liver (Sharma et al., 2022). Scopoletin (1, 5, and 10 mg/kg) significantly improves alanine transaminase (ALT), aspartate transaminase (AST), and alkaline phosphatase (ALP) activities in rat livers under toxicity induced by 100 mg/kg isoniazid, 300 mg/kg rifampicin, and 700 mg/kg pyrazinamide (Sharma et al., 2023).

 2.4.2 Chronic liver injury 2.4.2.1 Alcoholic fatty liver disease

Lee et al. reported that orally administered scopoletin (0.05%, w/w) decreased lipid contents in the liver and plasma and the activities of hepatic lipogenic enzymes in alcohol plus 35% kcal high-fat diet (HFD)-induced mice. The potential mechanism for these effects was modulation of AMP-activated protein kinase (AMPK)-sterol regulatory element-binding protein 1C (SREBP-1c) pathway-mediated lipogenesis in HFD-induced mice. The hepatoprotective effect of scopoletin is associated with its stimulation of the antioxidant defense system (Lee et al., 2014). In alcohol-fed rats, scopoletin regulates AMPK and the toll-like receptor 4 (TLR4)/myeloid differentiation major response gene 88 (MyD88)/NF-κB pathway and alleviates alcoholic hepatic steatosis and inflammation (Lee and Lee, 2015). In addition, Lee et al. reported that scopoletin (0.01 and 0.05 g/L) weakened chronic alcohol-induced insulin resistance and activated the antioxidant defense system through regulation of genes involved in liver glucose and antioxidant metabolism (Lee and Lee, 2015). Scopoletin is among the predominant compounds in the inner shell of chestnut (Castanea crenata) and has protective effects on ethanol-induced oxidative damage in vivo. Its hepatoprotective effects are associated with inhibition of lipid accumulation, peroxidation, and reinforcement of the antioxidant defense system in ethanol-induced mice. Scopoletin (50 μg/mL) increases antioxidant enzyme activities (SOD, catalase, glutathione peroxidase, and glutathione reductase) in alcohol-induced HepG2 cells (Noh et al., 2011).

 2.4.3 Non-alcoholic fatty liver disease

In the HFD-induced obesity mice model, scopoletin (0.01% and 0.05% in diet) may mitigate NAFLD and prevent the development of liver fibrosis by regulating lipid metabolism and inflammation. The specific mechanism involves reduction of liver lipid accumulation, improvement in insulin resistance, and reduction in inflammatory factors (TNF-α, IL-6, and IFNγ), chemokine monocyte chemoattractant protein-1 (MCP-1), and leptin levels (Ham et al., 2016). Administration of scopoletin to HFD-fed mice decreases the body weight, liver weight, and serum levels for lipids and liver damage markers (ALT and AST) and regulates the AMPK/SREBP signaling pathway (Park et al., 2017). Scopoletin promotes palmitic acid-induced intracellular accumulation of triglycerides (TGs) and total cholesterol in HepG2 cells (Kim et al., 2017a). Scopoletin (6.25–50 μmol/L) inhibits endoplasmic reticulum stress and reactive oxygen species (ROS) production in primary liver cells of rats and reduces c-Jun N-terminal kinase (JNK) phosphorylation to prevent palmitic acid- and bile acid-induced liver cell death (Wu et al., 2022).

 2.5 Effects on the cardiovascular system 2.5.1 Hypotensive activity

Ojewole and Adesina, (1983) observed that scopoletin isolated from Tetrapleura tetraptera fruit had non-specific spasmolytic activity on smooth muscles(Ojewole and Adesina, 1983). Subsequently, Oliveira et al. proposed that, with regard to scopoletin derived from the roots of Brunfelsia hopeana, the non-specific spasmolitic action is exerted through interference with the mobilization of intracellular calcium from norepinephrine (NE)-sensitive stores (Oliveira et al., 2001), and the release of sarcoplasmic reticulum Ca2+ induced by NE is inhibited, resulting in vasodilation of aortic rings (Iizuka et al., 2007). Wigati et al. reported that scopoletin decreases systolic pressure (SBP), diastolic pressure (DBP), and mean arterial blood pressure (MABP) in dexamethasone-induced mice. The mechanism is associated with the activity of an angiotensin-converting enzyme (ACE) inhibitor and the antioxidant activity of scopoletin (Wigati et al., 2017). Recently, scopoletin (0.01, 0.1, 1, 2, and 5 mg/kg, p.o.) has been shown to have antihypertensive effects on chronic and acute hypertensive mice induced by administration of angiotensin II. Scopoletin decreases the pharmacodynamic parameters for SBP and DBP by 75% and 92.8%, respectively (Lagunas-Herrera et al., 2019). Among the complications associated with hypertension, the onset of intracerebral hemorrhage is a devastating stage and is the most disabling type of stroke with the highest mortality rate. Zhang et al. observed that scopoletin improves rat ischemia induced by collagenase injection by reducing the expression of brain edema and other inflammatory mediators, such as TNF-α and IL-1β (Zhang et al., 2021).

 2.5.2 Anti-atherosclerotic activity

The relevant literature clearly indicates that lipid accumulation (Cartolano et al., 2018), inflammation (Geovanini and Libby, 2018), and oxidative stress (Förstermann et al., 2017) are the most important risk factors for atherosclerosis. Scopoletin (10 μg/mL) attenuates lipid accumulation and inflammation in the aorta in HFD-induced apolipoprotein E-deficient (ApoE−/−) mice, which reduces vascular inflammation by AMPK activation to suppress the expression of cell-cycle regulators (cyclin and cyclin-dependent kinase adhesion molecule) in human aortic smooth muscle cells (Park et al., 2017). Subsequently, Garg et al. observed that scopoletin (the main component isolated from Convolvulus pluricaulis extract, 0.4 mg/kg) significantly decreases the levels of atherogenic lipid biomarkers, atherogenic index, and MDA and increases the levels of HDL-C and GSH in tyloxapol-induced hyperlipidemia rats (Garg et al., 2018). In addition, Batra et al. reported that orally administered scopoletin (1, 5, and 10 mg/kg) reduces total cholesterol, low-density lipoprotein (LDL), and TG contents and improves the plasma atherosclerosis index and Castelli risk index in the high-fructose high-fat diet (HFHFD)-induced dyslipidemia model of Wistar rats (Batra et al., 2023a).

 2.5.3 Anti-myocardial infarction activity

Recently, in an isoproterenol-induced myocardial infarction rat model, pretreatment with scopoletin (25 and 50 mg/kg) was observed to significantly reduce the heart-to-body weight ratio, cardiac diagnostic markers, MDA content, inflammatory markers, and apoptotic markers (Rong et al., 2023). In addition, Li et al. reported that scopolamine induces endothelial-dependent relaxation mediated through the NO and prostacyclin pathways, thereby alleviating acute myocardial ischemia (Li et al., 2023).

 2.6 Antidiabetic activity

Diabetes mellitus may be the fastest-growing metabolic disease in the world. Approximately 2.5%–7% of the global population suffers from diabetes, which is a leading cause of illness and death. In diabetes, chronic hyperglycemia results from an interruption of carbohydrate and fat metabolism owing to insufficient insulin secretion, insufficient insulin function, or both (Rauf et al., 2017).

Scopoletin regulates hyperglycemia and diabetes. In the streptozotocin (STZ)-induced diabetic rat model, scopoletin has hypoglycemic and lipid-lowering effects (Verma et al., 2013; Al-Zuaidy et al., 2016). Choi et al. reported that scopoletin (0.01%) ameliorates hyperglycemia and hepatic steatosis in HFD- and STZ-induced diabetic mice through suppression of lipid biosynthesis and the TLR4–MyD88 pathways (Choi et al., 2017). In addition, scopoletin enhances the postprandial blood glucose levels by inhibiting the activity of carbohydrate digestive enzymes (α-glucosidase and α-amylase) in STZ-induced diabetes mice (Jang et al., 2018).

In 3T3-L1 adipocytes and high-glucose-induced HepG2 cells, scopoletin (10, 20, and 50 µM) improves insulin resistance and enhances glucose uptake by activating the PI3K/Akt signaling pathway (Zhang et al., 2010; Jang et al., 2020). Scopoletin (10 and 25 μM) improves insulin sensitivity in methylglyoxal-induced FL83B hepatocytes by activating the PPARγ/Akt pathway and restoring the plasma translocation of GLUT2 (Chang et al., 2015). In addition, improvement in insulin sensitivity in response to scopoletin (1 mg/kg/day, p.o.) can activate the AMPK and the IRS1–PI3K–Akt pathways in pancreatic β cells of high-fructose diet (HFHFD) rats and improves glucose homeostasis in HFHFD-induced diabetes rats (Kalpana et al., 2019; Batra et al., 2023b). Scopoletin (1–5 µM) stimulates insulin secretion by the KATP channel-dependent pathway in INS-1 pancreas β cells (Park et al., 2022). Furthermore, scopoletin (5, 10, 25, and 50 μM) protects INS-1 pancreatic β cells from glycotoxicity induced by high glucose and thus has potential as a drug to protect pancreatic β cells (Park and Han, 2023). Lee and Kim showed that scopoletin has potent inhibitory activity on both advanced glycation end-product (AGE) formation and rat lens aldose reductase (RLAR) in an in vitro bioassay, with an IC50 of 2.93 ± 0.06 μM and 22.51 ± 2.01 μM, respectively (Lee et al., 2010). The accumulation of AGEs is associated with an increase in the risk of fracture in patients with type 2 diabetes and has a direct adverse effect on bone quality (Yamamoto and Sugimoto, 2016). In vitro studies have revealed that scopoletin (1–20 µM) improves osteoclast formation in diabetes through RANKL and enhances osteoclast formation in diabetes by inducing BMP-2 and Runx2. Oral administration of 10 mg/kg scopoletin promotes the formation of bone trabeculae and collagen fibers in the femoral epiphysis and metaphysis of type 2 diabetes mice (Lee et al., 2021). Aldose reductase (AR) is a crucial rate-limiting enzyme that contributes to cataract induction among patients with diabetes. Scopoletin (10 and 50 mg/kg) mitigates diabetes cataract formation through inhibiting AR activity, polyol accumulation, and GSH generation in galactose-fed rats (Kim et al., 2013). To further explore the specific mechanism by which scopoletin alleviates diabetes retinopathy, Pan et al reported that scopoletin protected retinal ganglion cells from high glucose-induced damage through ROS-dependent p38 and JNK signaling cascades in a high glucose-induced retinal ganglia cell model (Pan et al., 2022). Diabetes nephropathy is among the most common microvascular complications of type 1 and type 2 diabetes; it is observed in approximately 40% of diabetes patients and is the main cause of chronic kidney disease worldwide (Vučić Lovrenčić et al., 2023). Scopoletin inhibits the proliferation of rat glomerular mesangial cells, reduces extracellular matrix proliferation and cell hypertrophy, reduces extracellular matrix protein accumulation, reduces the expression of the crucial fibrotic factor TGF-β and connective tissue growth factor, inhibits renal fibrosis, and thus improves diabetes glomerulosclerosis (Liang et al., 2021).

 2.7 Effect of scopoletin on neurodegenerative disorders

A neurodegenerative disorder indicates the progressive loss of functions and structures and neuronal cell death arising from different conditions, such as genetic and environmental factors (Gay et al., 2020). Motor neuron degeneration is an important pathological process in many types of nervous system diseases. Motor neuron disease is characterized by chronic progressive degeneration of motor neurons. Many studies have shown that scopoletin has a neuroprotective effect, which is mainly affected via 1) inhibition of monoamine oxidase (MAO) and acetylcholinesterase (AChE), 2) reduction of oxidative damage and chronic inflammation, and 3) protection of the activity of neurotrophic factors.

2.7.1 Anti-Alzheimer’s disease activity

Monoamine oxidase can be used to treat neurological disorders as a validated drug target (Carradori and Petzer, 2015). Its main function is to catalyze the oxidative deamination of neurotransmitters and biogenic amines (Edmondson et al., 2004). Yun et al. observed that scopoletin suppresses MAO in a dose-dependent manner with an IC50 value of 19.4 μg/mL (Yun et al., 2001). Furthermore, scopoletin (80 mg/kg, i.p.) is a reversible and selective MAO inhibitor causing an increase in the levels of dopamine and its metabolite (DOPAC) in the mouse brain (Mogana et al., 2013; Basu et al., 2016).

Acetylcholine (ACh) is widely distributed in the brain. The cholinergic system plays a role in crucial physiological processes, such as attention, learning, memory, stress response, wakefulness, and sleep, or sensory information (Ferreira-Vieira et al., 2016). Scopoletin can serve as an inhibitor of AChE, as indicated by the pharmacophore-based virtual screening method. The IC50 for AChE inhibition is 168.6 µM and 0.27 ± 0.02 mM (Rollinger et al., 2004; Mogana et al., 2013). Scopoletin shows AChE inhibitory activity in the range of 13.92%–34.18% at a concentration of 100 μg/mL (Suchaichit et al., 2018).

Neuronal cell death is an important feature of neurodegenerative disorders. In SH-SY5Y cells subject to hydrogen peroxide (H2O2) injury, scopoletin (5 μΜ) attenuates neurodegeneration via restoration of antioxidant enzyme activity, reduction in cell apoptosis, and activation of the SIRT1–ADAM10 signaling pathway, which is implicated in reduction in amyloid β (Aβ) production (Gay et al., 2020). In addition, Aβ is the main component of neuritic plaques in Alzheimer’s disease (AD) (Greenberg et al., 2020). Administration of 23 mg/kg scopoletin ameliorates the detrimental impacts of Aβ deposition on memory and learning among 5XFAD transgenic mice under a HFD diet, which is associated with microglia-enhanced phagocytic capacity and weakened microglia M1 phenotype activation (Medrano-Jiménez et al., 2019). Subsequently, Kashyap et al. proposed that scopoletin improves Aβ42-induced neurotoxicity and H2O2-induced cytotoxicity in PC12 cells. This effect may mediate inhibition of Aβ42 aggregation, AChE, butyrylcholinesterase, Aβ-site precursor protein-cleaving enzyme 1, MAO-B, and oxidative stress (Kashyap et al., 2020).

In conclusion, the imbalance of AChE and MAO, nerve cell death, and Aβ deposition may lead to cognitive and memory impairment. In cholinergically impaired and age-impaired mice models, scopoletin induces a significant increase in presynaptic activity-dependent acetylcholine release, enhances long-term potentiation (LTP) in the hippocampus, and exerts memory-improving properties (Hornick et al., 2011). The stimulatory role of Convolvulus pluricaulis extracts (500 mg/kg, scopoletin as the active ingredient), which modulate synaptic plasticity in the hippocampal cornu ammonis, enhances LTP and reduces long-term depression, which are the two major synaptic plasticity forms of memory formation (Das R. et al., 2020).

 2.7.2 Anti-Parkinsonism disease activity

Although the pathogenesis of Parkinson’s disease (PD) is not entirely resolved, it has been reported that excessive production of ROS, mitochondrial dysfunction, neuroinflammation, and environmental toxins can promote the loss of dopaminergic neurons in PD (Ryan et al., 2015). Rotenone-induced Sprague‒Dawley (SD) rats and SH-SY5Y cell models have shown that scopoletin inhibits cell apoptosis and oxidative stress by activating DJ-1–Nrf2–antioxidant response element (ARE) signaling (Narasimhan et al., 2019). In the same model, scopoletin attenuates rotenone-induced apoptosis of dopaminergic neurons in SD rats. The mechanism involves inhibition of the mitochondrial pathway of internal apoptosis, regulated by the Bcl2 family (Kishore Kumar et al., 2017). In addition, scopoletin (2.5 mM) is an antioxidant, reducing mitochondrial dysfunction and oxidative stress caused by an increase in ROS concentrations so as to restore motor ability and enhance the mitochondrial and cellular health of dopaminergic neurons in a Drosophila fly model of PD (Pradhan et al., 2020).

 2.7.3 Anti-Huntington’s activity

In a 3-nitropropionic acid-induced model of Huntington’s disease, administration of 20 mg/kg scopoletin attenuates motor deficits and oxidative damage in rats where it improves behavioral parameters (locomotor, rotarod, and narrow beam walking activity) and biochemical parameters (MDA, SOD, GSH, and nitrite) (Kaur et al., 2016).

 2.8 Anti-mental disorder

Worldwide, the prevalence of mental illness is approximately 25%. The mental illness mentioned in this paper refers to the medical concept of mental pain defined in the DSM-5 diagnostic criteria traditionally used for research. However, due to its long-term effects, mental illness is also considered a disability (Littlewood, 2001; Sayce and Boardman, 2008).

2.8.1 Anti-anxiety activity

Biebersteinia multifida root extract (45 mg/kg, i.p., including scopoletin) exhibits an anxiolytic effect that shows the same anti-anxiety effect as that of diazepam but lasts longer for 90 min (Monsef-Esfahani et al., 2013). In the Freund’s adjuvant-induced chronic inflammation anxiety mouse model, scopoletin (50 mg/kg, i.p.) exerts an anxiolytic effect through ameliorating anxiety-like behaviors, for which the mechanism is associated with suppression of the NF-κB/MAPK signaling pathways involving anti-inflammatory activities and regulation of the excitatory/inhibitory receptor balance (Luo et al., 2020).

 2.8.2 Anti-schizophrenia activity

Scopoletin at a specific dose of 0.1 mg/kg can alleviate the positive symptoms of schizophrenia. Scopoletin exerts anti-climbing and anti-stereotypy effects on apomorphine-induced cage climbing and methamphetamine-induced stereotypy behaviors, respectively, in mice (Pandy and Vijeepallam, 2017).

 2.8.3 Anti-depressant activity

Scopoletin (10–100 mg/kg, p.o.) shows particular antidepressant-like effects, as observed in the tail suspension test. Antidepressant effects are associated with the interaction of serotonergic (5-HT2A/2C receptors), noradrenergic (α1-and α2-adrenoceptor), and dopaminergic (D1 and D2 receptors) systems (Capra et al., 2010).

 2.9 Anti-oxidant activity

Scopoletin hinders oxidation in the ABTS, diphenyl-2-picrylhydrazyl (DPPH), FRAP, and β-carotene bleaching assays with half-maximal effective concentration (EC50) values of 5.62 ± 0.03 μM, 0.19 ± 0.01 mM, 0.25 ± 0.03 mM, and 0.65 ± 0.07 mM, respectively (Mogana et al., 2013). Scopoletin scavenges xanthine/xanthine oxidase-generated superoxide anions in a dose-dependent manner while xanthine oxidase activity is maintained and enhances the activity of endogenous antioxidant enzymes, such as SOD, catalase, and GSH (Shaw et al., 2003; Panda and Kar, 2006). Furthermore, scopoletin inhibits xanthine oxidase, maintains mitochondrial functioning to reduce ROS amounts, and suppresses LDL oxidation mediated by either Cu2+ or free radicals generated with an azo compound (Thuong et al., 2005). In addition, scopoletin shows antioxidant potential against DPPH (IC50 = 0.82 mg/mL) and NO (IC50 = 0.64 mg/mL) radicals (Sam-Ang et al., 2023).

 2.10 Miscellaneous properties 2.10.1 Anti-gout-lowering uric acid activity

Ding et al. showed that scopoletin (100 and 200 mg/kg, i.p.) causes a significant reduction in uric acid activity associated with potassium oxonate by decreasing the serum uric acid level and enhancing urine urate (Ding et al., 2005), although the mechanism is not clear. Scopoletin (200 mg/kg, p.o.) remarkably lowers the serum uric acid level of a yeast extract in potassium oxonate-induced mice; the therapeutic mechanisms are associated with inhibition of the activity of hepatic xanthine oxidase and promotion of uric acid excretion (Zeng et al., 2017).

 2.10.2 Anti-allergic activity

Scopoletin (50 μΜ) exerts anti-allergic activity mainly by inhibiting the production of cytokines (IL-4, IL-5 IL-10, and IFN-γ) and suppressing nuclear factor and GATA3 expression in activated T cells and PMA-/ionomycin-induced EL-4 T cells (Cheng et al., 2012).

 2.10.3 Anti-vitiligo activity

Vitiligo is a skin disease. The death or loss-of-function of skin melanocytes leads to partial discoloration of the skin (Pichler et al., 2006). Ahn et al. reported that scopoletin increases melanin synthesis in B16F10 cells by activating cAMP-responsive CREB phosphorylation and microphthalmia-associated transcription factor (MITF), resulting in an increase in the expression of tyrosinase (Ahn et al., 2014). In addition, scopoletin (40 μg/mL) stimulates melanin synthesis through activation of the cAMP/PKA/p38 MAPK pathway in B16 melanoma cells (Kim et al., 2017b). Furthermore, scopoletin (10, 20, and 25 μΜ) enhances melanogenesis responses in zebrafish and B16F10 cells, which is associated with increases in melanin content and expression of tyrosinase-related protein 1 and MITF (Heriniaina et al., 2018).

 2.10.4 Anti-aging activity

For human lung fibroblasts, scopoletin has anti-aging effects, which promotes autophagy induction via inactivation of p53 and enhance FoxO transportation, thereby inducing anti-aging-related autophagy and longevity (Nam and Kim, 2015). In HaCaT human keratinocytes with UVB, scopoletin (30, 100, and 300 µM) inhibits the expression of pro-inflammatory cytokines and matrix metallopeptidase (MMP)-1 by inhibiting the phosphorylation of p38 MAPK (Kim et al., 2018).

 2.10.5 Immunomodulatory activity

Alkorashy et al. demonstrated that scopoletin (50 μg/mL) stimulates U937-derived macrophages and significantly affects the expression of certain phagocytosis-linked genes (Alkorashy et al., 2020). Scopoletin (10 and 100 μΜ) suppresses ConA- and LPS-induced adaptive immune cell activation (Lee et al., 2017).

 2.10.6 Anti-nociceptive activity

Scopoletin, found in a Polygala sabulosa hydroalcoholic extract (0.01–10 mg/kg, i.p.), inhibits the acetic acid-induced visceral nociceptive response (Meotti et al., 2006). In addition, scopoletin (10 mg/kg, i.p.) counteracts nociception induced by glutamate in mice (Ribas et al., 2008).

 2.10.7 Anti-spinal cord injury activity

In a rat model of spinal cord injury, scopoletin (100 mg/kg, i.p.) improves locomotion 325 recovery and motor neuronal loss through stimulation of autophagy by triggering the AMPK/mammalian 326 target of the rapamycin (mTOR) signaling pathway (Zhou et al., 2020).

 2.10.8 Facilitating the digestion activity

Sun et al. preliminarily confirmed that scopoletin isolated from Cynachum auriculatum has an anti-functional dyspepsia effect (Sun et al., 2024). Scopoletin remarkably prevents acid reflux esophagitis production, with a similar efficiency to that of standard anti-secretory agents (ranitidine and lansoprazole) through its anti-inflammatory and anti-secretory attributes, such as its pro-kinetic activity, which can accelerate gastric emptying and intestinal transit (Mahattanadul et al., 2011). The potential mechanism is partially ascribed to the active component stimulating the 5-HT4 receptor (Nima et al., 2012).

 2.10.9 Inducing the expression of latent HIV

Reversing the incubation period of HIV-1 can promote the killing of infected cells, which is crucial for treatment strategies. In HIV-1 latently infected Jurkat T cell lines, scopoletin (2.0 mM) can significantly influence the incubation period of HIV-1 without cytotoxicity in a dose-dependent manner (Zhu et al., 2023).

 2.10.10 Inducing metabolomic profile disturbances

Yao et al. evaluated the metabolic effects of scopoletin in zebrafish embryos using non-targeted metabolomics methods. Exposure to scopoletin (2.1, 6.2, and 18.5 μg/mL) resulted in significant metabolic disorders, mainly involving phosphonate and phosphinate metabolism, vitamin B6 metabolism, histidine metabolism, sphingolipid metabolism, and folate biosynthesis (Yao et al., 2022).

 2.10.11 Ameliorating nephrotoxicity

Scopoletin (50 mg/kg/once daily, i.p.), via the Keap1–Nrf2/HO-1 and IκBα–P65–NF-κB–P38/MAPK signaling pathways, effectively improves renal function, oxidative stress biomarkers, and inflammatory mediators in vancomycin-treated rats (Khalaf et al., 2022).

 3 Pharmacokinetics of scopoletin

Pharmacokinetics is the study of the time course of the absorption, metabolism, distribution, and excretion of a drug, compound, or novel chemical entity upon its administration to the body (Fan and de Lannoy, 2014). Pharmacokinetics research provides compound-/drug-specific data to determine doses and dosing routes for individual patients, minimize toxicity, and offer a cornerstone for illnesses (Visser, 2018).

3.1 Absorption, metabolism, and elimination

Absorption, metabolism, and elimination transformations of scopoletin are widely used for monitoring its possible effects on different lifestyle-related disorders.

Following intragastric administration of 50 mg/kg scopoletin in rats, Xia et al. used high-performance liquid chromatography (HPLC) to tentatively detect the parameters (T max (min) = 10, C max (g/m) = 8.2 ± 0.8, T 1/2 (min) = 14.1 ± 0.6, AUCt (g min/mL) = 145.9 ± 11.8, and Ke (min−1) = 0.051 ± 0.005) associated with the absorption process by rat plasma (Xia et al., 2007). Given the low sensitivity of the HPLC method, it is unsuitable to study the in vivo absorption characteristics of scopoletin in detail. Therefore, Liu et al. studied its pharmacokinetics by HPLC/tandem mass spectrometry (Liu et al., 2011; Zeng et al., 2015; Li et al., 2019). The average percentage of scopoletin excreted from urine, above the dose administered, was 14.93%, and the cumulative biliary excretion of scopoletin above the dose administered was 0.16% after oral administration of Glehniae Radix extract to male SD rats (Liu et al., 2011). The results revealed that less than 15% of the analytes unchanged from the extract were excreted in the urine and less than 1% of the analytes unchanged from the extract were excreted in the bile, indicating that scopoletin undergoes major metabolism in the body. A pharmacokinetic study on rats after oral administration of scopoletin (5, 10, and 20 mg/kg) revealed that the oral bioavailability following a dose of 5 mg/kg was 6.62% ± 1.72%, for a dose of 10 mg/kg, it was 5.59% ± 1.16%, and for 20 mg/kg 5.65% ± 0.75% in the rat plasma (Zeng et al., 2015). Pharmacokinetic studies of dog plasma after oral administration of scopoletin (10, 25, and 50 mg/kg) showed that the bioavailability was 7.08%, 5.87%, and 5.69%, respectively (Zhao et al., 2019), similar to the bioavailability of coumarin (3.40% ± 2.60%) (Ritschel et al., 1977). Thus, these results indicated the statistical similarity of the oral bioavailability among the three p.o. groups and thus was found to be independent of the delivery of the administered dose. Zhang et al. applied the UHPLC-LTQ-Orbitrap-MS method to study the pharmacokinetics of scopoletin in dog plasma after intravenous (1 mg/kg) and oral administration (10, 25, and 50 mg/kg). The main relevant measurement parameters were as follows: AUC0-t (ng/h/mL) = 186.54 ± 36.45, 131.83 ± 19.23, 277.78 ± 35.12, and 528.19 ± 45.78; AUC0-∞ (ng/h/mL) = 197.97 ± 35.21, 140.43 ± 21.10, 284.69 ± 39.87, and 546.61 ± 51.28; T 1/2 (h) = 2.05 ± 0.27, 2.36 ± 0.45, 1.87 ± 0.21, and 1.65 ± 0.45; C max (ng/mL) = 423.23 ± 39.45, 85.47 ± 15.78, 253.78 ± 45.27, and 410.79 ± 57.19; and CL/F (L/kg/h) = 5.05 ± 0.89, 71.22 ± 15.23, 87.87 ± 15.56, and 91.47 ± 17.28 (Zhao et al., 2019). Li et al. reported that in rats administered 100 mg/kg scopoletin by gavage, the relevant pharmacokinetic parameters are as follows: AUC0-t (μg/L/h) = 203 ± 29.5; AUC0-∞ (μg/L/h) = 206 ± 29.1; T 1/2 (min): 69.6 ± 5.4; C max (μg/mL) = 72.7 ± 8.7; and CL/F (L/kg/min) = 418.9 ± 36.8 (Tian et al., 2023). Li et al. reported that, after the oral administration of 30 mg/kg scopoline, which is a metabolite of scopoletin, significant differences in certain parameters were observed between male and female rats (p < 0.05), i.e., AUC (9783.33 ± 157.61 ng/mL/min vs. 12,966.66 ± 1771.97 ng/mL/min), T max (14.00 ± 5.48 min vs. 6.67 ± 2.58 min), and CL/F (3.07 ± 0.05 L/min/kg vs. 2.36 ± 0.36 L/min/kg). Further investigation is needed to elucidate the potential mechanism of gender differences; however, the maximal excretion rates of scopoletin were 31.68 μg/h and 25.58 μg/h in male and female rats, respectively (Li et al., 2019).

Coumarin is quickly absorbed from the human gastrointestinal tract and is thoroughly metabolized by the liver, and only 2%–6% of the coumarin enters the systemic circulation intact (Ritschel et al., 1977; Ritschel et al., 1979). Scopoletin is a coumarin analog, and its rapid absorption, metabolism, and excretion from the human body may explain the poor bioavailability (Zeng et al., 2015). One study has shown that scopoletin is eliminated by first-order kinetics after intraperitoneal injection of Ding Gong Teng in mice. It showed the characteristics of a two-compartment open model: rapid absorption, rapid distribution, rapid action, and slow elimination. After intramuscular injection of Ding Gong Teng (scopoletin content: 2030 mg/L) in rabbits, the absorption showed double peaks: the first peak appeared at 8.08 min, and the concentration of scopoletin was 145.45 μg/L; the second peak appeared at 2.45 h, and the scopoletin concentration was 48.66 μg/L (Min et al., 2000). The pharmacokinetic study of Ding Gong Teng injection in rabbits showed that scopoletin was eliminated quickly, the elimination rate constant was 0.56 h, the half-life was 1.81 h, and the concentration at 4 h after administration was 5.32 μg/L. An additional study reported that scopoletin was well-absorbed in a human colon adenocarcinoma cell line model, indicating that it is well-absorbed in the gut lumen (Galkin et al., 2009). The aforementioned results suggest that scopoletin undergoes extensive metabolism in the body. Wang et al. determined that hepatic injury does not significantly influence the pharmacokinetics of scopoletin (Wang et al., 2018). The reason for this may be that cytochrome P450 enzymes had underwent partial change in the process of liver injury. It is also possible that scopoletin is not a P-glycoprotein substrate (Nabekura et al., 2015; Yang et al., 2015), which would explain the decrease in the bioavailability of scopoletin. The bioavailability of scopoletin is low (approximately 6.0%) (Zeng et al., 2017), which may be associated with its low water solubility and instability in physiological media. It may also reflect limited solubility, poor absorption and metabolism, or decomposition in the gastrointestinal tract (Issell et al., 2008).

Nevertheless, after oral administration of a Hedyotis diffusa extract (4.837 g/kg equivalent to 30.45 mg/kg of scopoletin), scopoletin was rapidly absorbed into the circulatory system in rats, and the half-life and average retention time were more than 10 h (Chen et al., 2018), indicating that the clearance rate of scopoletin in the plasma was slow.

 3.2 Distribution

Following oral administration of 6 g/kg of Angelicae Pubescentis Radix extract to rats at the lower limit of quantification levels (2.16 ng/mL), scopoletin could not be determined in the rat plasma. Analysis of its tissue distribution showed that scopoletin was extensively distributed in multiple tissues, particularly the heart, liver, and kidneys, reflecting its pharmacological roles (Chang et al., 2013).

The pharmacokinetic deficiencies and outlook for scopoletin can be briefly summarized as follows: 1) the optimal method to investigate the pharmacokinetics of scopoletin requires clarification; 2) there are distinct differences in pharmacokinetic parameters between mice of different genders, and additional studies should be conducted to explore the underlying mechanism of gender differences; 3) the pharmacokinetic parameters of scopoletin have only been studied in mice/rat and rabbit models.

 4 Toxicology of scopoletin

No strict boundary is proposed to portray or differentiate favorable or detrimental chemicals. The degree of harmfulness and safety seems to depend on the chemical dose. Therefore, this concept has become the hub of modern toxicology, meaning that dose determines toxicity (Hayes and Dixon, 2017).

4.1 Toxicity

As indicated by the acute toxicity test, scopoletin failed to generate treatment-associated mortality and abnormal performance at the limit test dose (2000 mg/kg, p.o.) for 14 days in SD rats (Tabana et al., 2016). This research shows the safety of scopoletin at the dose level, and, therefore, the LD50 value of scopoletin for oral toxicity is > 2000 mg/kg. Jamuna et al. observed rats for 14 days after administration of oral doses of 10, 50, and 100 mg/kg scopoletin and detected no obvious acute toxicity signs, no net gain or loss of body weight, or gross behavioral variation (Jamuna et al., 2015). In vivo experiments have administered a dose of 50–200 mg/kg (i.p.) scopoletin to SD rats and ICR mice (Ding et al., 2005; Pan et al., 2010; Yao et al., 2012). Table 3 summarizes the reported dosages of scopoletin for different animals. Thus, previous research has defined scopoletin as a relatively safe natural product, but there is a lack of long-term toxicity studies on animals. Strict experiments in vivo should be conducted for improved estimation of the side effects of scopoletin to ensure its safe use.

Dose range of scopoletin examined in animal models.

Strain Animal model Administration approach Experimental duration Tested dosage Result Reference
SD rats Ether-induced arthritis model i.p. 23 days 50 and 100 mg/kg Suppressed new vessel formation Pan et al. (2010)
ICR mice Murine air pouch model i.p. 6 h 50, 100, and 200 mg/kg Inhibited monosodium urate crystal-induced inflammation Yao et al. (2012)
SD rats Drug-induced liver injury model p.o. 21 days 1.5 and 10 mg/kg Decreased ALT, AST, and ALP levels Sharma et al. (2023)
Wistar male rats Type IV collagenase I was injected into the left striatum 6 weeks 100 mg/kg Reduced the expression of brain edema and inhibited inflammation Zhang et al. (2021)
Wistar rats HFHFD-induced dyslipidemia model p.o. 60 days 1.5 and 10 mg/kg Reduced TG, TC, and LDL-H and improved plasma atherosclerosis index and Castelli risk index Batra et al. (2023a)
Albino male rats Isoproterenol-induced myocardial infarction model p.o. 28 days 50 mg/kg Reduced heart to body weight ratio, cardiac diagnostic markers, inflammatory markers, and apoptotic markers Rong et al. (2023)
db/db mice p.o. 10 weeks 10 mg/kg Decreased weight and increased the serum RANKL/OPG ratio Lee et al. (2021)
ICR mice Potassium oxonate-induced hyperuricemia i.p. 1 h 50, 100, and 200 mg/kg Decreased hyperuricemia Ding et al. (2005)
SD rats Acute oral toxicity p.o. 14 days 2000 mg/kg Did not produce any considerable toxic behavioral effects Tabana et al. (2016)
Athymic nude mice HCT116 cell xenograft mouse model p.o. 21 days 50, 100, and 200 mg/kg/day Suppressed tumor growth by 94.7% relative to the vehicle-treated group
Female Swiss albino mice Acute oral toxicity p.o. 14 days 10, 50, and 100 mg/kg Possessed high safety profile Jamuna et al. (2015)
Swiss albino mice Cerulein-induced acute pancreatitis i.p. 6 h 10 mg/kg Improved acute pancreatitis Leema and Tamizhselvi (2018)
Female Swiss mice Carrageenan-induced pleurisy i.p. 4.5 h 0.1, 1, and 5 mg/kg Decreased neutrophil migration Pereira Dos Santos Nascimento et al. (2016)
Female Swiss mice Forced swimming test, tail suspension test, or open-field test p.o. 1 h 0.1, 1, 10, and 100 mg/kg Antidepressant-like action Capra et al. (2010)
Swiss mice Acetic acid-induced visceral nociceptive i.p. 0.5 h 0.01, 0.1, 1, and 10 mg/kg Improved visceral and inflammatory pain Meotti et al. (2006)
Swiss albino mice i.p. 4 weeks 80 mg/kg Increased brain DA and decreased DOPAC Basu et al. (2016)
Female Wistar rats T4-induced p.o. 1 week 0.5 and 1.0 mg/kg/day Anti-hyperthyroid Panda and Kar (2006)
Wistar albino rats STZ-induced diabetic rats p.o. 6 weeks 1 mg/kg Decreased blood glucose level and lipid level Verma et al. (2013)
C57BL/6N mice STZ-induced diabetic rats 11 weeks 0.01%, w/w Ameliorates steatosis and inflammation Choi et al. (2017)
SD rats HFFD-induced type 2 diabetes p.o. 45 days 1 mg/kg/day Improves insulin sensitivity Kalpana et al. (2019)
SD rats HFHFD-induced diabetes model p.o. 74 days 1.5 and 10 mg/kg/day Reversed insulin resistance Batra et al. (2023b)
SD rats Galactose-fed rats p.o. 2 weeks 10, 50 mg/kg/day Kim et al. (2013)
C57BL/6 mice CFA-induced anxiety p.o. 2 weeks 2, 10, and 50 mg/kg Ameliorates anxiety-like behaviors Luo et al. (2020)
4.2 Cytotoxicity

Scopoletin cytotoxicity has been assessed in numerous cell types in previous in vitro research, such as cancer cells, normal cells, immune cells, and nerve cells, illustrating that scopoletin is a relatively safe natural product. Table 4 summarizes the reported dosages of scopoletin for different cell lines.

Cytotoxic effects of scopoletin in different cell lines.

Cell line Species Category Detection method Tested concentration or IC50 Result Reference
PC3 Human Androgen adenocarcinoma cell MTT assay 33, 66, 133, 266, and 533 mg/mL (72 h), IC50 = 157 ± 25 mg/mL Inhibited cell proliferation Liu et al. (2001)
HL-60 Human Leukemia cell line MTT assay 0.025, 0.05, 0.1, 0.2, and 0.5 mg/mL (24 h) IC50 = 0.5 mg/mL Induced apoptosis via activation of NF-κB and caspase-3 Kim et al. (2005)
A375 Human Melanoma cell MTT assay 6, 12, 24, 30, 48, and 60 μΜ (24 h) Inhibited cell proliferation and induced apoptosis Khuda-Bukhsh et al. (2010)
KKU-100 Human Cholangiocarcinoma cell line MTT assay 250, 300, 350, 400, and 500 μΜ (72 h) IC50 = 486.2 ± 1.5 µM Induced cell apoptosis Asgar et al. (2015)
KKU-M214 Human Cholangiocarcinoma cell line MTT assay 50, 300, 350, 400, and 500 (72 h) IC50 = 493.5 ± 4.7 µM Induced cell apoptosis
H69 cells Human Bile duct epithelial cell line MTT assay (20–72 h) IC50 > 500 µM Lower cytotoxic effects
BW 5147 Human T-cell lymphoma cell line Trypan blue exclusion method 10, 50, 100, and 500 μg/mL (72 h) Inhibited cell proliferation Barreiro Arcos et al. (2006); Manuele et al. (2006)
EC50 = 251 ± 15 μg/mL
MCF-7 Human Human breast adenocarcinoma MTT assay 297.17 ± 7.99 μg/mL Inhibited cell proliferation Nasseri et al. (2022)
KKU-100 Human Cholangiocarcinoma cell line Sulforhodamine B assay 0.08, 0.16, 0.33, 0.65, 1.3, and 2.6 mM (24–48 h), IC50 24 h = 1.92 mM IC50 48 h = 0.89 mM Anti-migration effect Khunluck et al. (2019)
DoTc2 Human Cervical cancer cell lines Cell counting assay 3.56, 6.12, 12.5, 25, 50, and 100 μM (24 h) IC50 = 25 μM Triggered apoptosis and cell cycle arrest and inhibited cell invasion Tian et al. (2019)
SiHa Human Cervical cancer cell lines Cell counting assay 3.56, 6.12, 12.5, 25, 50, and 100 μM (24 h) IC50 = 15 μM
HeLa Human Cervical cancer cell lines Cell counting assay 3.56, 6.12.12.5, 25, 50, and 100 μM (24 h) IC50 = 7.5 μM
C33A Human Cervical cancer cell lines Cell counting assay 3.56, 6.12, 12.5, 25, 50, and 100 μM (24 h) IC50 = 25 μM
HCvEpC Human Normal cell Cell counting assay 3.56, 6.12,12.5, 25, 50, and 100 μM (24 h) IC50 = 90 μM
KKU-100/KKU-213B Human Cholangiocarcinoma cell MTT assay 1, 2, 3, and 4 mg/mL (24 h, 48 h, and 72 h) Antiproliferative Prompipak et al. (2021)
IC50 = 1.06 ± 0.03 mg/mL, 2.14 ± 0.08 mg/mL
RAW 264.7 Mouse Murine macrophage cell line MTT assay 1, 5, 10, 25, and 50 μg/mL, did not affect the cell viability Kim et al. (2004)
RAW 264.7 Mouse Murine macrophage cell line MTT assay 1, 10, 25, and 50 μg/mL, did not affect the cell viability Inhibited iNOS Kim et al. (1999)
RAW 264.7 Mouse Murine macrophage cell line MTT assay 30, 100, and 300 μΜ (20 h) Anti-inflammatory Yao et al. (2012)
RA-FLS Human Fibroblast-like synoviocytes MTT assay 10, 20, 30, 40, and 50 μΜ (24 h, 48 h) Inhibited proliferation, migration, and invasion Chen et al. (2022)
HASMCs Human Airway smooth muscle cells CCK-8 assay Inhibited proliferation Fan et al. (2022)
Fibroblast-like synoviocytes Mouse Adjuvant arthritis rat cells MTT assay 125, 250, 500, and 1,000 μΜ (24 h) Ying et al. (2009)
Fibroblast-like synoviocytes Mouse Adjuvant arthritis rat cells MTT assay 15, 30, and 60 mΜ (24 h) did not display remarkable cytotoxicity Anti-rheumatoid arthritis Dou et al. (2013)
INS-1 pancreatic β cells Mouse Pancreatic β cells MTT assay 5, 10, 20, 25, 50, and 100 µM Stimulated the secretion of insulin Park and Han (2023); Park et al. (2022)
RGC-5 cell Mouse Retinal ganglion cell MTT assay 62.5, 125, 250, and 500 mM (6 h) Protected RGC-5 cells exposed to high-glucose environments Pan et al. (2022)
RGMCs HBZY-1 cells Mouse Mesangial cell MTT assay 0.01, 5, 0.1, and 1 μM (48 h) Inhibited rat glomerular mesangial cells proliferation and ECM proliferation and cell hypertrophy Liang et al. (2021)
SH-SY5Y cells Human Dopaminergic cell MTT assay 1, 5, 10, and 50 μM (24 h) Attenuated neurodegeneration Gay et al. (2020)
PC12 cells Mouse Nerve cell MTT assay 10, 20, and 40 μM Anti-amyloidogenic and anti-cholinesterase Kashyap et al. (2020)
EL-4 T cells Mouse T-lymphoma cell Trypan blue dye exclusion 1, 10, 25, and 50 μM Attenuates allergy Cheng et al. (2012)
B16F10 cells Mouse Melanoma cells Crystal violet assay 0.1, 1, 10, 20, and 50 μΜ (24 h) Increases melanin synthesis Ahn et al. (2014)
B16F10 cells Mouse Melanoma cells MTT assay 0–40 μg/mL (24 h) Stimulates melanogenesis Kim et al. (2017a)
B16F10 cells Mouse Melanoma cells MTT assay 0.5, 10, 25, 50, 100, 150, 200, and 250 µM (48 h) Stimulates melanogenesis Heriniaina et al. (2018)
IMR 90 Human Lung fibroblast cells MTT assay 1, 2, 4.8, and 16 μΜ (24 h) Anti-aging Nam and Kim (2015)
HaCaT keratinocytes Human Fibroblasts MTT assay 0.5, 5, 15, 50, 150, 250, and 500 µM (24 h) Downregulated MMP-1 expression Kim et al. (2018)
U937 Human Macrophage cell line CytoTox96 LDH-release kit 10, 50, and 100 μg/mL No detectable cytotoxic effects Acharya et al. (2013)
U937 Human Monocytic cell line MTT assay 12.5, 25, 50, 100, 200, and 400 μg/mL No detectable cytotoxic effects Alkorashy et al. (2020)
Caco-2 Human Colonic adenocarcinoma WST-1 cytotoxicity assay 250 mM No detectable cytotoxic effects Galkin et al. (2009)
HUVECs Human Human endothelial cell MTS assay IC50 = 0.73 μM Antitumor Tabana et al. (2016)
3T3-L1 cells Mouse Embryo fibroblasts MTT assay 5, 10, 25, 50, and 100 mM (24 h) Did not affect the viability Jang et al. (2018)
5 Conclusion and future research prospects

In summary, this review summarizes the multiple physiological effects of scopoletin, confirming its significant positive effects on different illnesses, as stated previously. Consequently, many therapeutic intervention measures should be proposed in accordance with the potential mechanisms of the active agent and its derivatives. Moreover, as a natural compound, scopoletin provides a safer alternative for pharmaceutical applications targeting hepatic, neural, and cancer illnesses. Considering the therapeutic activities and the weak oral bioavailability of scopoletin, a large number of its derivatives and pharmaceutical dosages can be designed. Shi et al. considered isoxazole-based hybrids of scopoletin as an efficient chemical modification that improved the anticancer activity of scopoletin(Shi et al., 2017). The 2-fluorobenzylpyridinium derivative is the most potent tested compound, with an IC50 value of 0.215 ± 0.015 μM, which is significantly ameliorated compared with that of scopoletin (Khunnawutmanotham et al., 2016). Multiple substituted 8,8-dimethyl-8H-pyrano [2,3-f] chromen-2-ones (chromeno-coumarin hybrids) have been synthesized based on scopoletin as vasorelaxing agents. Compared with the parent molecule scopoletin, the sensitivity of these derivatives to experimental tissues was increased by 29.40–70.89 times (Singh et al., 2020). In addition, Soluplus-based scopoletin micelles (Sco-Ms) have been produced using a simple thin-film hydration technique, and the oral bioavailability of Sco-Ms was enhanced by 438% compared with that of free scopoletin. Oral delivery of Sco-Ms showed distinctly higher hypouricemic efficiency in hyperuricemic mice compared with that of scopoletin (Zeng et al., 2020). Polymeric nanoparticle encapsulation of scopoletin induced massive apoptosis in the human melanoma cell line A375 (Bhattacharyya et al., 2011).

The poor solubility of scopoletin limits the oral absorption and bioavailability of the compound. Therefore, methods to improve the bioavailability of scopoletin, reduce its toxicity, develop a suitable method for administration, and improve its clinical efficacy should be the focus of future research. In addition, scopoletin is a constituent in many edible plants and food products and thus could be developed as a health food and functional food. Further research on human subjects should be conducted to guarantee its safety, and decomposition products in the human body should be assessed to ensure its safe application in treatments. Similarly, further efforts should be made to verify the effects of food supplements, explore their diverse effects on humans and elucidate the mechanisms of action.

 Author contributions

X-YG: writing–original draft, writing–review and editing, and investigation. X-YL: Writing–original draft. C-YZ: Writing–original draft. C-YB: Writing–review and editing.

 Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

 Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 References Abdullah N. H. Salim F. Ahmad R. (2016). Chemical constituents of Malaysian U. Cordata var. ferruginea and their in vitro α-glucosidase inhibitory activities. Molecules 21 (5), 525. 10.3390/molecules21050525 Acharya D. Bogati B. Risal P. (2013). Scopoletin reduces intracellular survival of Salmonella typhi within U937 human macrophage cell line in vitro . Afr. J. Microbiol. Res. 1 (6), 47–51. Ahmadi N. Mohamed S. Sulaiman Rahman H. Rosli R. (2019). Epicatechin and scopoletin-rich Morinda citrifolia leaf ameliorated leukemia via anti-inflammatory, anti-angiogenesis, and apoptosis pathways in vitro and in vivo . J. Food Biochem. 43 (7), e12868. 10.1111/jfbc.12868 Ahn M. J. Hur S. J. Kim E. H. Lee S. H. Shin J. S. Kim M. K. (2014). Scopoletin from Cirsium setidens increases melanin synthesis via CREB phosphorylation in B16F10 cells. Korean J. Physiol. Pharmacol. 18 (4), 307–311. 10.4196/kjpp.2014.18.4.307 Alkorashy A. I. Doghish A. S. Abulsoud A. I. Ewees M. G. Abdelghany T. M. Elshafey M. M. (2020). Effect of scopoletin on phagocytic activity of U937-derived human macrophages: insights from transcriptomic analysis. Genomics 112 (5), 3518–3524. 10.1016/j.ygeno.2020.03.022 Al-Zuaidy M. H. Hamid A. A. Ismail A. Mohamed S. Abdul Razis A. F. Mumtaz M. W. (2016). Potent antidiabetic activity and metabolite profiling of melicope lunu-ankenda leaves. J. Food Sci. 81 (5), C1080–C1090. 10.1111/1750-3841.13293 Antika L. Meilawati L. Dewi R. Tasfiyati A. Septama A. (2023). Scopoletin: anticancer potential and mechanism of action. Asian Pac. J. Trop. Biomed. 13 (1), 1. 10.4103/2221-1691.367685 Asgar M. A. Senawong G. Sripa B. Senawong T. (2015). Scopoletin potentiates the anti-cancer effects of cisplatin against cholangiocarcinoma cell lines. Bangladesh J. Pharmacol. 10 (1), 69–77. 10.3329/bjp.v10i1.21202 Baggieri M. Gioacchini S. Borgonovo G. Catinella G. Marchi A. Picone P. (2023). Antiviral, virucidal and antioxidant properties of Artemisia annua against SARS-CoV-2. Biomed. Pharmacother. 168, 115682. 10.1016/j.biopha.2023.115682 Bak S. G. Lim H. J. Won Y. S. Lee S. Cheong S. H. Lee S. J. (2022). Regulatory effects of Lycium barbarum extract and isolated scopoletin on atopic dermatitis-like skin inflammation. Biomed. Res. Int. 2022, 2475699. 10.1155/2022/2475699 Barreiro Arcos M. L. Cremaschi G. Werner S. Coussio J. Ferraro G. Anesini C. (2006). Tilia cordata Mill. Extracts and scopoletin (isolated compound): differential cell growth effects on lymphocytes. Phytother. Res. 20 (1), 34–40. 10.1002/ptr.1798 Basu M. Mayana K. Xavier S. Balachandran S. Mishra N. (2016). Effect of scopoletin on monoamine oxidases and brain amines. Neurochem. Int. 93, 113–117. 10.1016/j.neuint.2016.01.001 Batra G. K. Anand A. Sharma S. Sharma S. Bhansali S. Patil A. N. (2023a). Scopoletin improves glucose homeostasis in the high-fructose high-fat diet-induced diabetes model in wistar rats. J. Med. Food 26 (4), 270–274. 10.1089/jmf.2022.K.0153 Batra G. K. Mothsara C. Sharma S. Anand A. Bhatia A. Bhansali S. (2023b). Dose-response evaluation of scopoletin, a phytochemical, in a high-fructose high-fat diet-induced dyslipidemia model in wistar rats. J. Med. Food 26 (5), 319–327. 10.1089/jmf.2022.K.0120 Beh H. K. Seow L. J. Asmawi M. Z. Abdul Majid A. M. Murugaiyah V. Ismail N. (2012). Anti-angiogenic activity of Morinda citrifolia extracts and its chemical constituents. Nat. Prod. Res. 26 (16), 1492–1497. 10.1080/14786419.2011.562208 Bhattacharyya S. S. Paul S. De A. Das D. Samadder A. Boujedaini N. (2011). Poly (lactide-co-glycolide) acid nanoencapsulation of a synthetic coumarin: cytotoxicity and bio-distribution in mice, in cancer cell line and interaction with calf thymus DNA as target. Toxicol. Appl. Pharmacol. 253 (3), 270–281. 10.1016/j.taap.2011.04.010 Buathong R. Chamchumroon V. Schinnerl J. Bacher M. Santimaleeworagun W. Kraichak E. (2019). Chemovariation and antibacterial activity of extracts and isolated compounds from species of Ixora and Greenea (Ixoroideae, Rubiaceae). PeerJ 7, e6893. 10.7717/peerj.6893 Cai X. Yang J. Zhou J. Lu W. Hu C. Gu Z. (2013). Synthesis and biological evaluation of scopoletin derivatives. Bioorg Med. Chem. 21 (1), 84–92. 10.1016/j.bmc.2012.10.059 Capra J. C. Cunha M. P. Machado D. G. Zomkowski A. D. Mendes B. G. Santos A. R. (2010). Antidepressant-like effect of scopoletin, a coumarin isolated from Polygala sabulosa (Polygalaceae) in mice: evidence for the involvement of monoaminergic systems. Eur. J. Pharmacol. 643 (2-3), 232–238. 10.1016/j.ejphar.2010.06.043 Carpinella M. C. Ferrayoli C. G. Palacios S. M. (2005). Antifungal synergistic effect of scopoletin, a hydroxycoumarin isolated from Melia azedarach L. fruits. J. Agric. Food Chem. 53 (8), 2922–2927. 10.1021/jf0482461 Carradori S. Petzer J. P. (2015). Novel monoamine oxidase inhibitors: a patent review (2012 - 2014). Expert Opin. Ther. Pat. 25 (1), 91–110. 10.1517/13543776.2014.982535 Cartolano F. C. Pappiani C. Freitas M. C. P. Figueiredo Neto A. M. Carioca A. A. F. Damasceno N. R. T. (2018). Is lipid accumulation product associated with an atherogenic lipoprotein profile in Brazilian subjects? Arq. Bras. Cardiol. 110 (4), 339–347. 10.5935/abc.20180054 Chaingam J. Juengwatanatrakul T. Yusakul G. Kanchanapoom T. Putalun W. (2021). HPLC-UV-Based simultaneous determination of canthin-6-one alkaloids, quassinoids, and scopoletin: the active ingredients in eurycoma longifolia jack and eurycoma harmandiana pierre, and their anti-inflammatory activities. J. AOAC Int. 104 (3), 802–810. 10.1093/jaoacint/qsaa141 Chandrasekhar G. Shukla M. Kaul G. K R. Chopra S. Pandey R. (2023). Characterization and antimicrobial evaluation of anthraquinones and triterpenes from Rubia cordifolia. J. Asian Nat. Prod. Res. 25, 1110–1116. 10.1080/10286020.2023.2193698 Chang W. C. Wu S. C. Xu K. D. Liao B. C. Wu J. F. Cheng A. S. (2015). Scopoletin protects against methylglyoxal-induced hyperglycemia and insulin resistance mediated by suppression of advanced glycation endproducts (AGEs) generation and anti-glycation. Molecules 20 (2), 2786–2801. 10.3390/molecules20022786 Chang Y. X. Zhang Q. H. Li J. Zhang L. Guo X. R. He J. (2013). Simultaneous determination of scopoletin, psoralen, bergapten, xanthotoxin, columbianetin acetate, imperatorin, osthole and isoimperatorin in rat plasma by LC-MS/MS for pharmacokinetic studies following oral administration of Radix Angelicae Pubescentis extract. J. Pharm. Biomed. Anal. 77, 71–75. 10.1016/j.jpba.2012.12.031 Chen Q. Zhou W. Huang Y. Tian Y. Wong S. Y. Lam W. K. (2022). Umbelliferone and scopoletin target tyrosine kinases on fibroblast-like synoviocytes to block NF-κB signaling to combat rheumatoid arthritis. Front. Pharmacol. 13, 946210. 10.3389/fphar.2022.946210 Chen Q. Zhu L. Yip K. M. Tang Y. Liu Y. Jiang T. (2021). A hybrid platform featuring nanomagnetic ligand fishing for discovering COX-2 selective inhibitors from aerial part of Saussurea laniceps Hand.-Mazz. J. Ethnopharmacol. 271, 113849. 10.1016/j.jep.2021.113849 Chen X. Zhu P. Liu B. Wei L. Xu Y. (2018). Simultaneous determination of fourteen compounds of Hedyotis diffusa Willd extract in rats by UHPLC-MS/MS method: application to pharmacokinetics and tissue distribution study. J. Pharm. Biomed. Anal. 159, 490–512. 10.1016/j.jpba.2018.07.023 Cheng A. S. Cheng Y. H. Chang T. L. (2012). Scopoletin attenuates allergy by inhibiting Th2 cytokines production in EL-4 T cells. Food Funct. 3 (8), 886–890. 10.1039/c2fo30054k Chiang C. C. Cheng M. J. Peng C. F. Huang H. Y. Chen I. S. (2010). A novel dimeric coumarin analog and antimycobacterial constituents from Fatoua pilosa. Chem. Biodivers. 7 (7), 1728–1736. 10.1002/cbdv.200900326 Choi R. Y. Ham J. R. Lee H. I. Cho H. W. Choi M. S. Park S. K. (2017). Scopoletin supplementation ameliorates steatosis and inflammation in diabetic mice. Phytother. Res. 31 (11), 1795–1804. 10.1002/ptr.5925 Choi Y. G. Yeo S. Kim S. H. Lim S. (2012). Anti-inflammatory changes of gene expression by Artemisia iwayomogi in the LPS-stimulated human gingival fibroblast: microarray analysis. Arch. Pharm. Res. 35 (3), 549–563. 10.1007/s12272-012-0319-0 Collin M. Ginhoux F. (2019). Human dendritic cells. Semin. Cell Dev. Biol. 86, 1–2. 10.1016/j.semcdb.2018.04.015 Das R. Sengupta T. Roy S. Chattarji S. Ray J. (2020a). Convolvulus pluricaulis extract can modulate synaptic plasticity in rat brain hippocampus. Neuroreport 31 (8), 597–604. 10.1097/wnr.0000000000001446 Das S. Czuni L. Báló V. Papp G. Gazdag Z. Papp N. (2020b). Cytotoxic action of artemisinin and scopoletin on planktonic forms and on biofilms of Candida species. Molecules 25 (3), 476. 10.3390/molecules25030476 De LaCruz-Sánchez N. G. Gómez-Rivera A. Alvarez-Fitz P. Ventura-Zapata E. Pérez-García M. D. Avilés-Flores M. (2019). Antibacterial activity of Morinda citrifolia Linneo seeds against Methicillin-Resistant Staphylococcus spp. Microb. Pathog. 128, 347–353. 10.1016/j.micpath.2019.01.030 Ding Z. Dai Y. Hao H. Pan R. Yao X. Wang Z. (2008). Anti-inflammatory effects of scopoletin and underlying mechanisms. Pharm. Biol. 46 (12), 854–860. 10.1080/13880200802367155 Ding Z. Dai Y. Wang Z. (2005). Hypouricemic action of scopoletin arising from xanthine oxidase inhibition and uricosuric activity. Planta Med. 71 (2), 183–185. 10.1055/s-2005-837789 Dou Y. Tong B. Wei Z. Li Y. Xia Y. Dai Y. (2013). Scopoletin suppresses IL-6 production from fibroblast-like synoviocytes of adjuvant arthritis rats induced by IL-1β stimulation. Int. Immunopharmacol. 17 (4), 1037–1043. 10.1016/j.intimp.2013.10.011 Duggirala S. Nankar R. P. Rajendran S. Doble M. (2014). Phytochemicals as inhibitors of bacterial cell division protein FtsZ: coumarins are promising candidates. Appl. Biochem. Biotechnol. 174 (1), 283–296. 10.1007/s12010-014-1056-2 Edmondson D. E. Mattevi A. Binda C. Li M. Hubálek F. (2004). Structure and mechanism of monoamine oxidase. Curr. Med. Chem. 11 (15), 1983–1993. 10.2174/0929867043364784 Ezzat S. M. Abdallah H. M. Fawzy G. A. El-Maraghy S. A. (2012). Hepatoprotective constituents of Torilis radiata moench (apiaceae). Nat. Prod. Res. 26 (3), 282–285. 10.1080/14786419.2011.587422 Fan J. de Lannoy I. A. (2014). Pharmacokinetics. Biochem. Pharmacol. 87 (1), 93–120. 10.1016/j.bcp.2013.09.007 Fan Z. Tang D. Wu Q. Huang Q. Song J. Long Q. (2022). Scopoletin inhibits PDGF-BB-induced proliferation and migration of airway smooth muscle cells by regulating NF-κB signaling pathway. Allergol. Immunopathol. Madr. 50 (1), 92–98. 10.15586/aei.v50i1.517 Farah M. H. Samuelsson G. (1992). Pharmacologically active phenylpropanoids from Senra incana. Planta Med. 58 (1), 14–18. 10.1055/s-2006-961380 Ferreira-Vieira T. H. Guimaraes I. M. Silva F. R. Ribeiro F. M. (2016). Alzheimer's disease: targeting the cholinergic system. Curr. Neuropharmacol. 14 (1), 101–115. 10.2174/1570159x13666150716165726 Forino M. Tartaglione L. Dell'Aversano C. Ciminiello P. (2016). NMR-based identification of the phenolic profile of fruits of Lycium barbarum (goji berries). Isolation and structural determination of a novel N-feruloyl tyramine dimer as the most abundant antioxidant polyphenol of goji berries. Food Chem. 194, 1254–1259. 10.1016/j.foodchem.2015.08.129 Förstermann U. Xia N. Li H. (2017). Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ. Res. 120 (4), 713–735. 10.1161/circresaha.116.309326 Galkin A. Fallarero A. Vuorela P. M. (2009). Coumarins permeability in Caco-2 cell model. J. Pharm. Pharmacol. 61 (2), 177–184. 10.1211/jpp/61.02.0006 Garg G. Patil A. Singh J. Kaushik N. Praksah A. Pal A. (2018). Pharmacological evaluation of Convolvulus pluricaulis as hypolipidaemic agent in Triton WR-1339-induced hyperlipidaemia in rats. J. Pharm. Pharmacol. 70 (11), 1572–1580. 10.1111/jphp.13004 Gay N. H. Suwanjang W. Ruankham W. Songtawee N. Wongchitrat P. Prachayasittikul V. (2020). Butein, isoliquiritigenin, and scopoletin attenuate neurodegeneration via antioxidant enzymes and SIRT1/ADAM10 signaling pathway. RSC Adv. 10 (28), 16593–16606. 10.1039/c9ra06056a Geovanini G. R. Libby P. (2018). Atherosclerosis and inflammation: overview and updates. Clin. Sci. (Lond) 132 (12), 1243–1252. 10.1042/cs20180306 Greenberg S. M. Bacskai B. J. Hernandez-Guillamon M. Pruzin J. Sperling R. van Veluw S. J. (2020). Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat. Rev. Neurol. 16 (1), 30–42. 10.1038/s41582-019-0281-2 Ham J. R. Lee H.-I. Choi R.-Y. Sim M.-O. Choi M.-S. Kwon E.-Y. (2016). Anti-obesity and anti-hepatosteatosis effects of dietary scopoletin in high-fat diet fed mice. J. Funct. Foods 25, 433–446. 10.1016/j.jff.2016.06.026 Hayes A. W. Dixon D. (2017). Cornerstones of toxicology. Toxicol. Pathol. 45 (1), 57–63. 10.1177/0192623316675768 Heriniaina R. M. Dong J. Kalavagunta P. K. Wu H. L. Yan D. S. Shang J. (2018). Effects of six compounds with different chemical structures on melanogenesis. Chin. J. Nat. Med. 16 (10), 766–773. 10.1016/s1875-5364(18)30116-x Hornick A. Lieb A. Vo N. P. Rollinger J. M. Stuppner H. Prast H. (2011). The coumarin scopoletin potentiates acetylcholine release from synaptosomes, amplifies hippocampal long-term potentiation and ameliorates anticholinergic- and age-impaired memory. Neuroscience 197 (1), 280–292. 10.1016/j.neuroscience.2011.09.006 Iahtisham Ul H. Butt M. S. Randhawa M. A. Shahid M. (2019). Hepatoprotective effects of red beetroot-based beverages against CCl(4) -induced hepatic stress in Sprague Dawley rats. J. Food Biochem. 43 (12), e13057. 10.1111/jfbc.13057 Iizuka T. Nagumo S. Yotsumoto H. Moriyama H. Nagai M. (2007). Vasorelaxant effects of Acer nikoense extract and isolated coumarinolignans on rat aortic rings. Biol. Pharm. Bull. 30 (6), 1164–1166. 10.1248/bpb.30.1164 Issell B. F. Franke A. Fielding R. M. (2008). Pharmacokinetic study of Noni fruit extract. J. Diet. Suppl. 5 (4), 373–382. 10.1080/19390210802519671 Jamuna S. Karthika K. Paulsamy S. Thenmozhi K. Kathiravan S. Venkatesh R. (2015). Confertin and scopoletin from leaf and root extracts of Hypochaeris radicata have anti-inflammatory and antioxidant activities. Industrial Crops Prod. 70, 221–230. 10.1016/j.indcrop.2015.03.039 Jang J. H. Park J. E. Han J. S. (2018). Scopoletin inhibits α-glucosidase in vitro and alleviates postprandial hyperglycemia in mice with diabetes. Eur. J. Pharmacol. 834, 152–156. 10.1016/j.ejphar.2018.07.032 Jang J. H. Park J. E. Han J. S. (2020). Scopoletin increases glucose uptake through activation of PI3K and AMPK signaling pathway and improves insulin sensitivity in 3T3-L1 cells. Nutr. Res. 74, 52–61. 10.1016/j.nutres.2019.12.003 Ji J. Zhang Z. Peng Q. Hao L. Guo Y. Xue Y. (2022). The effects of qinghao-kushen and its active compounds on the biological characteristics of liver cancer cells. Evid. Based Complement. Altern. Med. 2022, 8763510. 10.1155/2022/8763510 Kai K. Mizutani M. Kawamura N. Yamamoto R. Tamai M. Yamaguchi H. (2008). Scopoletin is biosynthesized via ortho-hydroxylation of feruloyl CoA by a 2-oxoglutarate-dependent dioxygenase in Arabidopsis thaliana . Plant J. 55 (6), 989–999. 10.1111/j.1365-313X.2008.03568.x Kalpana K. Sathiya Priya C. Dipti N. Vidhya R. Anuradha C. V. (2019). Supplementation of scopoletin improves insulin sensitivity by attenuating the derangements of insulin signaling through AMPK. Mol. Cell Biochem. 453 (1-2), 65–78. 10.1007/s11010-018-3432-7 Kamino T. Shimokura T. Morita Y. Tezuka Y. Nishizawa M. Tanaka K. (2016). Comparative analysis of the constituents in Saposhnikoviae Radix and Glehniae Radix cum Rhizoma by monitoring inhibitory activity of nitric oxide production. J. Nat. Med. 70 (2), 253–259. 10.1007/s11418-016-0969-1 Kang S. Y. Sung S. H. Park J. H. Kim Y. C. (1998). Hepatoprotective activity of scopoletin, a constituent of Solanum lyratum. Arch. Pharm. Res. 21 (6), 718–722. 10.1007/bf02976764 Kang T. H. Pae H. O. Jeong S. J. Yoo J. C. Choi B. M. Jun C. D. (1999). Scopoletin: an inducible nitric oxide synthesis inhibitory active constituent from Artemisia feddei. Planta Med. 65 (5), 400–403. 10.1055/s-1999-14014 Kashyap P. Ram H. Shukla S. D. Kumar S. (2020). Scopoletin: antiamyloidogenic, anticholinesterase, and neuroprotective potential of a natural compound present in Argyreia speciosa roots by in vitro and in silico study. Neurosci. Insights 15, 2633105520937693. 10.1177/2633105520937693 Kaur M. Prakash A. Kalia A. N. (2016). Neuroprotective potential of antioxidant potent fractions from Convolvulus pluricaulis Chois. in 3-nitropropionic acid challenged rats. Nutr. Neurosci. 19 (2), 70–78. 10.1179/1476830515y.0000000022 Khalaf M. M. Hassan S. M. Sayed A. M. Abo-Youssef A. M. (2022). Ameliorate impacts of scopoletin against vancomycin-induced intoxication in rat model through modulation of Keap1-Nrf2/HO-1 and IκBα-P65 NF-κB/P38 MAPK signaling pathways: molecular study, molecular docking evidence and network pharmacology analysis. Int. Immunopharmacol. 102, 108382. 10.1016/j.intimp.2021.108382 Khuda-Bukhsh A. R. Bhattacharyya S. S. Paul S. Boujedaini N. (2010). Polymeric nanoparticle encapsulation of a naturally occurring plant scopoletin and its effects on human melanoma cell A375. Zhong Xi Yi Jie He Xue Bao 8 (9), 853–862. 10.3736/jcim20100909 Khunluck T. Kukongviriyapan V. Senggunprai L. Duangarsong W. Prawan A. (2019). The inhibition kinetics and potential anti-migration activity of NQO1 inhibitory coumarins on cholangiocarcinoma cells. Integr. Cancer Ther. 18, 1534735418820444. 10.1177/1534735418820444 Khunnawutmanotham N. Chimnoi N. Saparpakorn P. Techasakul S. (2016). Synthesis and anti-acetylcholinesterase activity of scopoletin derivatives. Bioorg Chem. 65, 137–145. 10.1016/j.bioorg.2015.12.002 Kim D. S. Cha S. B. Park M. C. Park S. A. Kim H. S. Woo W. H. (2017a). Scopoletin stimulates melanogenesis via cAMP/PKA pathway and partially p38 activation. Biol. Pharm. Bull. 40 (12), 2068–2074. 10.1248/bpb.b16-00690 Kim E. K. Kwon K. B. Shin B. C. Seo E. A. Lee Y. R. Kim J. S. (2005). Scopoletin induces apoptosis in human promyeloleukemic cells, accompanied by activations of nuclear factor kappaB and caspase-3. Life Sci. 77 (7), 824–836. 10.1016/j.lfs.2005.02.003 Kim H. G. Lee S. B. Lee J. S. Kim W. Y. Choi S. H. Son C. G. (2017b). Artemisia iwayomogi plus curcuma longa synergistically ameliorates nonalcoholic steatohepatitis in HepG2 cells. Evid. Based Complement. Altern. Med., 2017, 4390636. 10.1155/2017/4390636 Kim H. J. Jang S. I. Kim Y. J. Chung H. T. Yun Y. G. Kang T. H. (2004). Scopoletin suppresses pro-inflammatory cytokines and PGE2 from LPS-stimulated cell line, RAW 264.7 cells. Fitoterapia 75 (3-4), 261–266. 10.1016/j.fitote.2003.12.021 Kim H. L. Woo S. M. Choi W. R. Kim H. S. Yi C. Kim K. H. (2018). Scopoletin downregulates MMP-1 expression in human fibroblasts via inhibition of p38 phosphorylation. Int. J. Mol. Med. 42 (4), 2285–2293. 10.3892/ijmm.2018.3757 Kim J. Kim C. S. Lee Y. M. Sohn E. Jo K. Shin S. D. (2013). Scopoletin inhibits rat aldose reductase activity and cataractogenesis in galactose-fed rats. Evid. Based Complement. Altern. Med., 2013, 787138. 10.1155/2013/787138 Kim N. Y. Pae H. O. Ko Y. S. Yoo J. C. Choi B. M. Jun C. D. (1999). In vitro inducible nitric oxide synthesis inhibitory active constituents from Fraxinus rhynchophylla. Planta Med. 65 (7), 656–658. 10.1055/s-2006-960840 Kimura M. Kawahito Y. Obayashi H. Ohta M. Hara H. Adachi T. (2007). A critical role for allograft inflammatory factor-1 in the pathogenesis of rheumatoid arthritis. J. Immunol. 178 (5), 3316–3322. 10.4049/jimmunol.178.5.3316 Kishore Kumar S. N. Deepthy J. Saraswathi U. Thangarajeswari M. Yogesh Kanna S. Ezhil P. (2017). Morinda citrifolia mitigates rotenone-induced striatal neuronal loss in male Sprague-Dawley rats by preventing mitochondrial pathway of intrinsic apoptosis. Redox Rep. 22 (6), 418–429. 10.1080/13510002.2016.1253449 Kwon Y. S. Choi W. G. Kim W. J. Kim W. K. Kim M. J. Kang W. H. (2002). Antimicrobial constituents of Foeniculum vulgare. Arch. Pharm. Res. 25 (2), 154–157. 10.1007/bf02976556 Lagunas-Herrera H. Tortoriello J. Herrera-Ruiz M. Martínez-Henández G. B. Zamilpa A. Santamaría L. A. (2019). Acute and chronic antihypertensive effect of fractions, tiliroside and scopoletin from Malva parviflora. Biol. Pharm. Bull. 42 (1), 18–25. 10.1248/bpb.b18-00355 Lee E. J. Na W. Kang M. K. Kim Y. H. Kim D. Y. Oh H. (2021). Hydroxycoumarin scopoletin inhibits bone loss through enhancing induction of bone turnover markers in a mouse model of type 2 diabetes. Biomedicines 9 (6), 648. 10.3390/biomedicines9060648 Lee H. E. Yang G. Choi J. S. Lee J. Y. (2017). Suppression of primary splenocyte proliferation by Artemisia capillaris and its components. Toxicol. Res. 33 (4), 283–290. 10.5487/tr.2017.33.4.283 Lee H.-I. Lee M.-K. (2015a). Effects of scopoletin supplementation on insulin resistance and antioxidant defense system in chronic alcohol-fed rats. J. Korean Soc. Food Sci. Nutr. 44 (2), 173–181. 10.3746/jkfn.2015.44.2.173 Lee H. I. Lee M. K. (2015b). Coordinated regulation of scopoletin at adipose tissue-liver axis improved alcohol-induced lipid dysmetabolism and inflammation in rats. Toxicol. Lett. 237 (3), 210–218. 10.1016/j.toxlet.2015.06.016 Lee H. I. Yun K. W. Seo K. I. Kim M. J. Lee M. K. (2014). Scopoletin prevents alcohol-induced hepatic lipid accumulation by modulating the AMPK-SREBP pathway in diet-induced obese mice. Metabolism 63 (4), 593–601. 10.1016/j.metabol.2014.01.003 Lee J. Kim N. H. Nam J. W. Lee Y. M. Jang D. S. Kim Y. S. (2010). Scopoletin from the flower buds of Magnolia fargesii inhibits protein glycation, aldose reductase, and cataractogenesis ex vivo . Arch. Pharm. Res. 33 (9), 1317–1323. 10.1007/s12272-010-0904-z Lee S. H. Ding Y. Yan X. T. Kim Y. H. Jang H. D. (2013). Scopoletin and scopolin isolated from Artemisia iwayomogi suppress differentiation of osteoclastic macrophage RAW 264.7 cells by scavenging reactive oxygen species. J. Nat. Prod. 76 (4), 615–620. 10.1021/np300824h Leema G. Tamizhselvi R. (2018). Protective effect of scopoletin against cerulein-induced acute pancreatitis and associated lung injury in mice. Pancreas 47 (5), 577–585. 10.1097/mpa.0000000000001034 Lemos A. S. O. Florêncio J. R. Pinto N. C. C. Campos L. M. Silva T. P. Grazul R. M. (2020). Antifungal activity of the natural coumarin scopoletin against planktonic cells and biofilms from a multidrug-resistant Candida tropicalis strain. Front. Microbiol. 11, 1525. 10.3389/fmicb.2020.01525 Li B. Lu M. Chu Z. Lei S. Sun P. Xiong S. (2019). Evaluation of pharmacokinetics, bioavailability and urinary excretion of scopolin and its metabolite scopoletin in Sprague Dawley rats by liquid chromatography-tandem mass spectrometry. Biomed. Chromatogr. 33 (12), e4678. 10.1002/bmc.4678 Li J. Zhang C. Gong M. Wang M. (2018). Combination of artemisinin-based natural compounds from Artemisia annua L. for the treatment of malaria: pharmacodynamic and pharmacokinetic studies. Phytother. Res. 32 (7), 1415–1420. 10.1002/ptr.6077 Li S. Zhan J. Wang Y. Oduro P. K. Owusu F. B. Zhang J. (2023). Suxiao Jiuxin Pill attenuates acute myocardial ischemia via regulation of coronary artery tone. Front. Pharmacol. 14, 1104243. 10.3389/fphar.2023.1104243 Liang Y. Zeng X. Guo J. Liu H. He B. Lai R. (2021). Scopoletin and umbelliferone from Cortex Mori as protective agents in high glucose-induced mesangial cell as in vitro model of diabetic glomerulosclerosis. Chin. J. Physiol. 64 (3), 150–158. 10.4103/cjp.cjp_9_21 Littlewood R. (2001). From psychiatric patient to citizen: overcoming discrimination and social exclusion by liz Sayce. Basingstoke: macmillan. 2000. 280 pp. £13.99 (pb). ISBN 0 333 69890 8. Psychiatric Patient Citiz. Overcoming Discrimination Soc. Exclusion By Liz Sayce. Basingstoke Macmillan Br. J. Psychiatry 179 (2), 182. 10.1192/bjp.179.2.182 Liu M. Shi X. Yang W. Liu S. Wang N. Shi R. (2011). Quantitative analysis of nine coumarins in rat urine and bile after oral administration of Radix Glehniae extract by high-performance liquid chromatography-electrospray ionization tandem mass spectrometry. Biomed. Chromatogr. 25 (7), 783–793. 10.1002/bmc.1517 Liu X. L. Zhang L. Fu X. L. Chen K. Qian B. C. (2001). Effect of scopoletin on PC3 cell proliferation and apoptosis. Acta Pharmacol. Sin. 22 (10), 929–933. Luo L. Sun T. Yang L. Liu A. Liu Q. Q. Tian Q. Q. (2020). Scopoletin ameliorates anxiety-like behaviors in complete Freund's adjuvant-induced mouse model. Mol. Brain 13 (1), 15. 10.1186/s13041-020-0560-2 Mahattanadul S. Ridtitid W. Nima S. Phdoongsombut N. Ratanasuwon P. Kasiwong S. (2011). Effects of Morinda citrifolia aqueous fruit extract and its biomarker scopoletin on reflux esophagitis and gastric ulcer in rats. J. Ethnopharmacol. 134 (2), 243–250. 10.1016/j.jep.2010.12.004 Mamoon Ur R. Ali S. Alamzeb M. Igoli J. Clements C. Shah S. Q. (2014). Phytochemical and antitrypanosomal investigation of the fractions and compounds isolated from Artemisia elegantissima. Pharm. Biol. 52 (8), 983–987. 10.3109/13880209.2013.874534 Mandukhail S. U. Aziz N. Gilani A. H. (2010). Studies on antidyslipidemic effects of Morinda citrifolia (Noni) fruit, leaves and root extracts. Lipids Health Dis. 9, 88. 10.1186/1476-511x-9-88 Mankar M. Akhtar S. Kumar C. S. Ravi S. Kumar S. Gothlwal R. (2013). Evaluation of noni extract on mouse macrophages for its immune-enhancer property. Int. J. Phytomedicine 5 (4), 499. Manuele M. G. Ferraro G. Barreiro Arcos M. L. López P. Cremaschi G. Anesini C. (2006). Comparative immunomodulatory effect of scopoletin on tumoral and normal lymphocytes. Life Sci. 79 (21), 2043–2048. 10.1016/j.lfs.2006.06.045 Marealle A. I. Moyo A. A. Machumi F. Qwarse M. Chenyambuga Y. M. Heydenreich M. (2023). Antimycobacterial activity of scopoletin from ethanolic extract of Hymenodictyon floribundum (Hochst. and Steud.) B.L.Rob. Stem bark. Sci. Afr. 21, e01778. 10.1016/j.sciaf.2023.e01778 Medrano-Jiménez E. Jiménez-Ferrer Carrillo I. Pedraza-Escalona M. Ramírez-Serrano C. E. Álvarez-Arellano L. Cortés-Mendoza J. (2019). Malva parviflora extract ameliorates the deleterious effects of a high fat diet on the cognitive deficit in a mouse model of Alzheimer's disease by restoring microglial function via a PPAR-γ-dependent mechanism. J. Neuroinflammation 16 (1), 143. 10.1186/s12974-019-1515-3 Meerungrueang W. Panichayupakaranant P. (2014). Antimicrobial activities of some Thai traditional medical longevity formulations from plants and antibacterial compounds from Ficus foveolata. Pharm. Biol. 52 (9), 1104–1109. 10.3109/13880209.2013.877493 Meotti F. C. Ardenghi J. V. Pretto J. B. Souza M. M. d' Avila Moura J. Junior A. C. (2006). Antinociceptive properties of coumarins, steroid and dihydrostyryl-2-pyrones from Polygala sabulosa (Polygalaceae) in mice. J. Pharm. Pharmacol. 58 (1), 107–112. 10.1211/jpp.58.1.0013 Min W. Li_ling Z. Rui L. (2000). Determination of plasma concentration of total scopoletin by RP-HPLC. TRADITIONAL Chin. DRUG Res. Clin. Pharmacol. 1. Mishra N. Oraon A. Dev A. Jayaprakash V. Basu A. Pattnaik A. K. (2010). Anticonvulsant activity of Benkara malabarica (Linn.) root extract: in vitro and in vivo investigation. J. Ethnopharmacol. 128 (2), 533–536. 10.1016/j.jep.2010.01.042 Mogana R. Teng-Jin K. Wiart C. (2013). Anti-inflammatory, anticholinesterase, and antioxidant potential of scopoletin isolated from canarium patentinervium Miq. (Burseraceae kunth). Evid. Based Complement. Altern. Med., 2013, 734824. 10.1155/2013/734824 Mohamad Shalan N. A. Mustapha N. M. Mohamed S. (2016). Morinda citrifolia leaf enhanced performance by improving angiogenesis, mitochondrial biogenesis, antioxidant, anti-inflammatory and stress responses. Food Chem. 212, 443–452. 10.1016/j.foodchem.2016.05.179 Molokoane T. L. Kemboi D. Siwe-Noundou X. Famuyide I. M. McGaw L. J. Tembu V. J. (2023). Extractives from Artemisia afra with anti-bacterial and anti-fungal properties. Plants (Basel) 12 (19), 3369. 10.3390/plants12193369 Monsef-Esfahani H. R. Amini M. Goodarzi N. Saiedmohammadi F. Hajiaghaee R. Faramarzi M. A. (2013). Coumarin compounds of Biebersteinia multifida roots show potential anxiolytic effects in mice. Daru 21 (1), 51. 10.1186/2008-2231-21-51 Moon P. D. Lee B. H. Jeong H. J. An H. J. Park S. J. Kim H. R. (2007). Use of scopoletin to inhibit the production of inflammatory cytokines through inhibition of the IkappaB/NF-kappaB signal cascade in the human mast cell line HMC-1. Eur. J. Pharmacol. 555 (2-3), 218–225. 10.1016/j.ejphar.2006.10.021 More G. Lall N. Hussein A. Tshikalange T. E. (2012). Antimicrobial constituents of Artemisia afra jacq. Ex Willd. Against periodontal pathogens. Evid. Based Complement. Altern. Med. 2012, 252758. 10.1155/2012/252758 Muschietti L. Gorzalczany S. Ferraro G. Acevedo C. Martino V. (2001). Phenolic compounds with anti-inflammatory activity from Eupatorium buniifolium. Planta Med. 67 (8), 743–744. 10.1055/s-2001-18355 Nabekura T. Hiroi T. Kawasaki T. Uwai Y. (2015). Effects of natural nuclear factor-kappa B inhibitors on anticancer drug efflux transporter human P-glycoprotein. Biomed. Pharmacother. 70, 140–145. 10.1016/j.biopha.2015.01.007 Nahata A. Dixit V. K. (2012). Ameliorative effects of stinging nettle (Urtica dioica) on testosterone-induced prostatic hyperplasia in rats. Andrologia 44 (Suppl. 1), 396–409. 10.1111/j.1439-0272.2011.01197.x Nam H. Kim M. M. (2015). Scopoletin has a potential activity for anti-aging via autophagy in human lung fibroblasts. Phytomedicine 22 (3), 362–368. 10.1016/j.phymed.2015.01.004 Napiroon T. Bacher M. Balslev H. Tawaitakham K. Santimaleeworagun W. Vajrodaya S. (2018). Scopoletin from Lasianthus lucidus Blume (Rubiaceae): a potential antimicrobial against multidrug-resistant Pseudomonas aeruginosa . J. Appl. Pharm. Sci. 8 (9), 1–6. 10.7324/JAPS.2018.8901 Narasimhan K. K. S. Jayakumar D. Velusamy P. Srinivasan A. Mohan T. Ravi D. B. (2019). Morinda citrifolia and its active principle scopoletin mitigate protein aggregation and neuronal apoptosis through augmenting the DJ-1/nrf2/ARE signaling pathway. Oxid. Med. Cell Longev., 2019, 2761041. 10.1155/2019/2761041 Nasseri S. Delnavazi M. R. Shirazi F. H. Mojab F. (2022). Cytotoxic activity and phytochemical analysis of Artemisia haussknechtii boiss. Iran. J. Pharm. Res. 21 (1), e126917. 10.5812/ijpr-126917 Navarro-García V. M. Rojas G. Avilés M. Fuentes M. Zepeda G. (2011). In vitro antifungal activity of coumarin extracted from Loeselia mexicana Brand. Mycoses 54 (5), e569–e571. 10.1111/j.1439-0507.2010.01993.x Ng T. B. Liu F. Lu Y. Cheng C. H. Wang Z. (2003). Antioxidant activity of compounds from the medicinal herb Aster tataricus. Comp. Biochem. Physiol. C Toxicol. Pharmacol. 136 (2), 109–115. 10.1016/s1532-0456(03)00170-4 Nima S. Kasiwong S. Ridtitid W. Thaenmanee N. Mahattanadul S. (2012). Gastrokinetic activity of Morinda citrifolia aqueous fruit extract and its possible mechanism of action in human and rat models. J. Ethnopharmacol. 142 (2), 354–361. 10.1016/j.jep.2012.04.044 Noh J. R. Gang G. T. Kim Y. H. Yang K. J. Hwang J. H. Lee H. S. (2010). Antioxidant effects of the chestnut (Castanea crenata) inner shell extract in t-BHP-treated HepG2 cells, and CCl4-and high-fat diet-treated mice. Food Chem. Toxicol. 48 (11), 3177–3183. 10.1016/j.fct.2010.08.018 Noh J. R. Kim Y. H. Gang G. T. Hwang J. H. Lee H. S. Ly S. Y. (2011). Hepatoprotective effects of chestnut (Castanea crenata) inner shell extract against chronic ethanol-induced oxidative stress in C57BL/6 mice. Food Chem. Toxicol. 49 (7), 1537–1543. 10.1016/j.fct.2011.03.045 Ojewole J. A. Adesina S. K. (1983). Mechanism of the hypotensive effect of scopoletin isolated from the fruit of Tetrapleura tetraptera. Planta Med. 49 (1), 46–50. 10.1055/s-2007-969809 Oliveira E. J. Romero M. A. Silva M. S. Silva B. A. Medeiros I. A. (2001). Intracellular calcium mobilization as a target for the spasmolytic action of scopoletin. Planta Med. 67 (7), 605–608. 10.1055/s-2001-17355 Page G. Lebecque S. Miossec P. (2002). Anatomic localization of immature and mature dendritic cells in an ectopic lymphoid organ: correlation with selective chemokine expression in rheumatoid synovium. J. Immunol. 168 (10), 5333–5341. 10.4049/jimmunol.168.10.5333 Pan J. Liu H. Wu Q. Zhou M. (2022). Scopoletin protects retinal ganglion cells 5 from high glucose-induced injury in a cellular model of diabetic retinopathy via ROS-dependent p38 and JNK signaling cascade. Cent. Eur. J. Immunol. 47 (1), 20–29. 10.5114/ceji.2022.115710 Pan R. Dai Y. Gao X. H. Lu D. Xia Y. F. (2011a). Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways. Vasc. Pharmacol. 54 (1-2), 18–28. 10.1016/j.vph.2010.11.001 Pan R. Dai Y. Yang J. Li Y. Yao X. Xia Y. (2009). Anti-angiogenic potential of scopoletin is associated with the inhibition of ERK1/2 activation. Drug Dev. Res. 70 (3), 214–219. 10.1002/ddr.20297 Pan R. Gao X. Lu D. Xu X. Xia Y. Dai Y. (2011b). Prevention of FGF-2-induced angiogenesis by scopoletin, a coumarin compound isolated from Erycibe obtusifolia Benth, and its mechanism of action. Int. Immunopharmacol. 11 (12), 2007–2016. 10.1016/j.intimp.2011.08.012 Pan R. Gao X. H. Li Y. Xia Y. F. Dai Y. (2010). Anti-arthritic effect of scopoletin, a coumarin compound occurring in Erycibe obtusifolia Benth stems, is associated with decreased angiogenesis in synovium. Fundam. Clin. Pharmacol. 24 (4), 477–490. 10.1111/j.1472-8206.2009.00784.x Panda S. Kar A. (2006). Evaluation of the antithyroid, antioxidative and antihyperglycemic activity of scopoletin from Aegle marmelos leaves in hyperthyroid rats. Phytother. Res. 20 (12), 1103–1105. 10.1002/ptr.2014 Pandy V. Vijeepallam K. (2017). Antipsychotic-like activity of scopoletin and rutin against the positive symptoms of schizophrenia in mouse models. Exp. Anim. 66 (4), 417–423. 10.1538/expanim.17-0050 Park J. E. Han J. S. (2023). Scopoletin protects INS-1 pancreatic β cells from glucotoxicity by reducing oxidative stress and apoptosis. Toxicol Vitro 93, 105665. 10.1016/j.tiv.2023.105665 Park J. E. Kim S. Y. Han J. S. (2022). Scopoletin stimulates the secretion of insulin via a KATP channel-dependent pathway in INS-1 pancreatic β cells. J. Pharm. Pharmacol. 74 (9), 1274–1281. 10.1093/jpp/rgab143 Park S. H. Sung Y. Y. Nho K. J. Kim D. S. Kim H. K. (2017). Effects of Viola mandshurica on atherosclerosis and hepatic steatosis in ApoE[formula: see text] via the AMPK pathway. Am. J. Chin. Med. 45 (4), 757–772. 10.1142/s0192415x17500409 Patel M. R. Bhalodia Y. S. Pathak N. L. Patel M. S. Suthar K. Patel N. (2013). Study on the mechanism of the bronchodilatory effects of Cynodon dactylon (Linn.) and identification of the active ingredient. J. Ethnopharmacol. 150 (3), 946–952. 10.1016/j.jep.2013.09.053 Pereira Dos Santos Nascimento M. V. Arruda-Silva F. Gobbo Luz A. B. Baratto B. Venzke D. Mendes B. G. (2016). Inhibition of the NF-κB and p38 MAPK pathways by scopoletin reduce the inflammation caused by carrageenan in the mouse model of pleurisy. Immunopharmacol. Immunotoxicol. 38 (5), 344–352. 10.1080/08923973.2016.1203929 Pichler R. Sfetsos K. Badics B. Gutenbrunner S. Auböck J. (2006). Vitiligo patients present lower plasma levels of alpha-melanotropin immunoreactivities. Neuropeptides 40 (3), 177–183. 10.1016/j.npep.2006.03.001 Pradhan P. Majhi O. Biswas A. Joshi V. K. Sinha D. (2020). Enhanced accumulation of reduced glutathione by Scopoletin improves survivability of dopaminergic neurons in Parkinson's model. Cell Death Dis. 11 (9), 739. 10.1038/s41419-020-02942-8 Prompipak J. Senawong T. Sripa B. Ketterman A. J. Utaiwat S. Woranam K. (2021). Anticancer effects of the combined Thai noni juice ethanolic extracts and 5-fluorouracil against cholangiocarcinoma cells in vitro and in vivo . Sci. Rep. 11 (1), 14866. 10.1038/s41598-021-94049-z Ramírez-Reyes T. I. Aguilar-Colorado Á S. Murrieta-León D. L. Licona-Velázquez L. S. Bonilla-Landa I. Durán-Espinosa C. (2019). Identification of antibacterial phenolics in selected plant species from Mexican cloud forest by mass spectrometry dereplication. Chem. Biodivers. 16 (4), e1800603. 10.1002/cbdv.201800603 Rauf A. Imran M. Suleria H. A. R. Ahmad B. Peters D. G. Mubarak M. S. (2017). A comprehensive review of the health perspectives of resveratrol. Food Funct. 8 (12), 4284–4305. 10.1039/c7fo01300k Ren W. Wang Y. He Q. Zhou Y. Li C. Wang W. (2020). Chemical composition of Erycibe schmidtii and antiproliferative activity of scopoletin on immature dendritic cells. Nat. Prod. Res. 34 (18), 2581–2588. 10.1080/14786419.2018.1547292 Ribas C. M. Meotti F. C. Nascimento F. P. Jacques A. V. Dafre A. L. Rodrigues A. L. S. (2008). Antinociceptive effect of the Polygala sabulosa hydroalcoholic extract in mice: evidence for the involvement of glutamatergic receptors and cytokine pathways. Basic and Clin. Pharmacol. Toxicol. 103 (1), 43–47. 10.1111/j.1742-7843.2008.00245.x Ritschel W. A. Brady M. E. Tan H. S. (1979). First-pass effect of coumarin in man. Int. J. Clin. Pharmacol. Biopharm. 17 (3), 99–103. Ritschel W. A. Brady M. E. Tan H. S. Hoffmann K. A. Yiu I. M. Grummich K. W. (1977). Pharmacokinetics of coumarin and its 7-hydroxy-metabolites upon intravenous and peroral administration of coumarin in man. Eur. J. Clin. Pharmacol. 12 (6), 457–461. 10.1007/bf00561066 Rollinger J. M. Hornick A. Langer T. Stuppner H. Prast H. (2004). Acetylcholinesterase inhibitory activity of scopolin and scopoletin discovered by virtual screening of natural products. J. Med. Chem. 47 (25), 6248–6254. 10.1021/jm049655r Rong N. Yang R. Ibrahim I. A. A. Zhang W. (2023). Cardioprotective role of scopoletin on isoproterenol-induced myocardial infarction in rats. Appl. Biochem. Biotechnol. 195 (2), 919–932. 10.1007/s12010-022-04123-z Ryan B. J. Hoek S. Fon E. A. Wade-Martins R. (2015). Mitochondrial dysfunction and mitophagy in Parkinson's: from familial to sporadic disease. Trends Biochem. Sci. 40 (4), 200–210. 10.1016/j.tibs.2015.02.003 Sajti E. van Meeteren N. Kavelaars A. van der Net J. Gispen W. H. Heijnen C. (2004). Individual differences in behavior of inbred Lewis rats are associated with severity of joint destruction in adjuvant-induced arthritis. Brain Behav. Immun. 18 (6), 505–514. 10.1016/j.bbi.2003.12.004 Sam-Ang P. Phanumartwiwath A. Liana D. Sureram S. Hongmanee P. Kittakoop P. (2023). UHPLC-QQQ-MS and RP-HPLC detection of bioactive alizarin and scopoletin metabolites from Morinda citrifolia root extracts and their antitubercular, antibacterial, and antioxidant activities. ACS Omega 8 (32), 29615–29624. 10.1021/acsomega.3c03656 Sayce L. Boardman J. (2008). Disability rights and mental health in the UK: recent developments of the Disability Discrimination Act. Adv. Psychiatric Treat. 14 (4), 265–275. 10.1192/apt.bp.106.003103 Selim Y. A. Ouf N. H. (2012). Anti-inflammatory new coumarin from the Ammi majus L. Org. Med. Chem. Lett. 2 (1), 1. 10.1186/2191-2858-2-1 Seo E. J. Saeed M. Law B. Y. Wu A. G. Kadioglu O. Greten H. J. (2016). Pharmacogenomics of scopoletin in tumor cells. Molecules 21 (4), 496. 10.3390/molecules21040496 Sharma S. Anand A. Bhatia A. Sharma V. Singh A. K. Banerjee D. (2022). Pharmacological evaluation of scopoletin in the carbon tetrachloride-induced hepatotoxicity model in wistar rats. J. Pharm. Bioallied Sci. 14 (4), 201–206. 10.4103/jpbs.jpbs_333_22 Sharma S. Sharma V. Taneja S. Alka B. Anand A. Patil A. N. (2023). Scopoletin a potential phytochemical therapy for antitubercular treatment drug induced liver injury (ATT-DILI) model in Wistar rats. J. Complement. Integr. Med. 20, 797–803. 10.1515/jcim-2023-0168 Shaw C. Y. Chen C. H. Hsu C. C. Chen C. C. Tsai Y. C. (2003). Antioxidant properties of scopoletin isolated from Sinomonium acutum. Phytother. Res. 17 (7), 823–825. 10.1002/ptr.1170 Shi W. Hu J. Bao N. Li D. Chen L. Sun J. (2017). Design, synthesis and cytotoxic activities of scopoletin-isoxazole and scopoletin-pyrazole hybrids. Bioorg Med. Chem. Lett. 27 (2), 147–151. 10.1016/j.bmcl.2016.11.089 Shi Z. Li N. Chen C. Wang Y. Lei Z. Chen L. (2020). Novel NO-releasing scopoletin derivatives induce cell death via mitochondrial apoptosis pathway and cell cycle arrest. Eur. J. Med. Chem. 200, 112386. 10.1016/j.ejmech.2020.112386 Singh S. Agarwal K. Iqbal H. Yadav P. Yadav D. Chanda D. (2020). Synthesis and evaluation of substituted 8,8-dimethyl-8H-pyrano[2,3-f]chromen-2-one derivatives as vasorelaxing agents. Bioorg Med. Chem. Lett. 30 (1), 126759. 10.1016/j.bmcl.2019.126759 Suchaichit N. Kanokmedhakul S. Kanokmedhakul K. Moosophon P. Boonyarat C. Plekratoke K. (2018). Phytochemical investigation and acetylcholinesterase inhibitory activity of bark of Hymenodictyon orixense. Nat. Prod. Res. 32 (24), 2936–2939. 10.1080/14786419.2017.1389930 Sun J. Gou J. Qin L. Liu T. Huang Y. Lu Y. (2024). Screening of anti-functional dyspepsia compounds in Cynanchum auriculatum: a spectrum-effect relationship analysis, and ATP-binding cassette transporters inhibitor evaluation. J. Ethnopharmacol. 318 (Pt A), 116867. 10.1016/j.jep.2023.116867 Tabana Y. M. Hassan L. E. Ahamed M. B. Dahham S. S. Iqbal M. A. Saeed M. A. (2016). Scopoletin, an active principle of tree tobacco (Nicotiana glauca) inhibits human tumor vascularization in xenograft models and modulates ERK1, VEGF-A, and FGF-2 in computer model. Microvasc. Res. 107, 17–33. 10.1016/j.mvr.2016.04.009 Thuong P. T. Na M. Su N. D. Seong R. S. Lee Y. M. Sok D. E. (2005). Inhibitory effect of coumarins from Weigela subsessilis on low density lipoprotein oxidation. Biol. Pharm. Bull. 28 (6), 1095–1097. 10.1248/bpb.28.1095 Tian Q. Jin H. Huo X. Zhao Y. Wu W. Xu L. (2023). Comparative pharmacokinetics of scoparone and its metabolite scopoletin in normal and ANIT-induced intrahepatic cholestatic rats. Curr. Drug Metab. 24 (4), 303–311. 10.2174/1389200224666230510125610 Tian Q. Wang L. Sun X. Zeng F. Pan Q. Xue M. (2019). Scopoletin exerts anticancer effects on human cervical cancer cell lines by triggering apoptosis, cell cycle arrest, inhibition of cell invasion and PI3K/AKT signalling pathway. J. buon 24 (3), 997–1002. Tzeng T. C. Lin Y. L. Jong T. T. Chang C. M. J. (2007). Ethanol modified supercritical fluids extraction of scopoletin and artemisinin from Artemisia annua L. Sep. Purif. Technol. 56 (1), 18–24. 10.1016/j.seppur.2007.01.010 Verma A. Dewangan P. Kesharwani D. Kela S. P. (2013). Hypoglycemic and hypolipidemic activity of scopoletin (coumarin derivative) in streptozotocin induced diabetic rats. Int. J. Pharm. Sci. Rev. Res. 22 (1), 79–83. Visser M. (2018). Translating pharmacokinetic and pharmacodynamic data into practice. Vet. Clin. North Am. Exot. Anim. Pract. 21 (2), 169–182. 10.1016/j.cvex.2018.01.001 Vučić Lovrenčić M. Božičević S. Smirčić Duvnjak L. (2023). Diagnostic challenges of diabetic kidney disease. Biochem. Med. Zagreb. 33 (3), 030501. 10.11613/bm.2023.030501 Wang Y. Xing X. Cao Y. Zhao L. Sun S. Chen Y. (2018). Development and application of an UHPLC-MS/MS method for comparative pharmacokinetic study of eight major bioactive components from yin chen hao tang in normal and acute liver injured rats. Evid. Based Complement. Altern. Med., 2018, 3239785. 10.1155/2018/3239785 Wan Osman W. N. Che Ahmad Tantowi N. A. Lau S. F. Mohamed S. (2019). Epicatechin and scopoletin rich Morinda citrifolia (Noni) leaf extract supplementation, mitigated Osteoarthritis via anti-inflammatory, anti-oxidative, and anti-protease pathways. J. Food Biochem. 43 (3), e12755. 10.1111/jfbc.12755 Wigati D. Anwar K. Sudarsono S. Nugroho A. E. (2017). Hypotensive activity of ethanolic extracts of Morinda citrifolia L. Leaves and fruit in dexamethasone-induced hypertensive rat. J. Evid. Based Complement. Altern. Med. 22 (1), 107–113. 10.1177/2156587216653660 Wu Z. Geng Y. Buist-Homan M. Moshage H. (2022). Scopoletin and umbelliferone protect hepatocytes against palmitate- and bile acid-induced cell death by reducing endoplasmic reticulum stress and oxidative stress. Toxicol. Appl. Pharmacol. 436, 115858. 10.1016/j.taap.2021.115858 Xia Y. Dai Y. Wang Q. Liang H. (2007). Determination of scopoletin in rat plasma by high performance liquid chromatographic method with UV detection and its application to a pharmacokinetic study. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 857 (2), 332–336. 10.1016/j.jchromb.2007.07.023 Yamakawa M. Doh S. J. Santosa S. M. Montana M. Qin E. C. Kong H. (2018). Potential lymphangiogenesis therapies: learning from current antiangiogenesis therapies-A review. Med. Res. Rev. 38 (6), 1769–1798. 10.1002/med.21496 Yamamoto M. Sugimoto T. (2016). Advanced glycation end products, diabetes, and bone strength. Curr. Osteoporos. Rep. 14 (6), 320–326. 10.1007/s11914-016-0332-1 Yang X. W. Zhang C. Y. Zhang B. G. Lu Y. Luan J. W. Zheng Q. T. (2009). Novel coumarin and furan from the roots of Angelica pubescens f. biserrata. J. Asian Nat. Prod. Res. 11 (8), 698–703. 10.1080/10286020802619140 Yang Y. F. Xu W. Song W. Ye M. Yang X. W. (2015). Transport of twelve coumarins from Angelicae Pubescentis Radix across a MDCK-pHaMDR cell monolayer-an in vitro model for blood-brain barrier permeability. Molecules 20 (7), 11719–11732. 10.3390/molecules200711719 Yao W. Chen J. Lin Z. Wang N. Wang A. Wang B. (2022). Scopoletin induced metabolomic profile disturbances in zebrafish embryos. Metabolites 12 (10), 934. 10.3390/metabo12100934 Yao X. Ding Z. Xia Y. Wei Z. Luo Y. Feleder C. (2012). Inhibition of monosodium urate crystal-induced inflammation by scopoletin and underlying mechanisms. Int. Immunopharmacol. 14 (4), 454–462. 10.1016/j.intimp.2012.07.024 Ying L. Yue D. Mei L. Pan R. Luo Y. Xia Y. (2009). Scopoletin induces apoptosis of fibroblast-like synoviocytes from adjuvant arthritis rats by a mitochondrial-dependent pathway. Drug Dev. Res. 70, 378–385. 10.1002/ddr.20314 Yu N. Li N. Wang K. Deng Q. Lei Z. Sun J. (2021). Design, synthesis and biological activity evaluation of novel scopoletin-NO donor derivatives against MCF-7 human breast cancer in vitro and in vivo . Eur. J. Med. Chem. 224, 113701. 10.1016/j.ejmech.2021.113701 Yuan C. Wang M. H. Wang F. Chen P. Y. Ke X. G. Yu B. (2021). Network pharmacology and molecular docking reveal the mechanism of Scopoletin against non-small cell lung cancer. Life Sci. 270, 119105. 10.1016/j.lfs.2021.119105 Yun B. S. Lee I. K. Ryoo I. J. Yoo I. D. (2001). Coumarins with monoamine oxidase inhibitory activity and antioxidative coumarino-lignans from Hibiscus syriacus. J. Nat. Prod. 64 (9), 1238–1240. 10.1021/np0100946 Zapata Lopera Y. M. Jiménez-Ferrer E. Herrera-Ruiz M. Zamilpa A. González-Cortazar M. Rosas-Salgado G. (2022). New chromones from Bouvardia ternifolia (cav.) Schltdl with anti-inflammatory and immunomodulatory activity. Plants (Basel) 12 (1), 1. 10.3390/plants12010001 Zeng Y. Li S. Wang X. Gong T. Sun X. Zhang Z. (2015). Validated LC-MS/MS method for the determination of scopoletin in rat plasma and its application to pharmacokinetic studies. Molecules 20 (10), 18988–19001. 10.3390/molecules201018988 Zeng Y. Ma Y. Yang Z. Mao J. Zheng Y. (2020). Antihyperuricemic efficacy of Scopoletin-loaded Soluplus micelles in yeast extract/potassium oxonate-induced hyperuricemic mice. Drug Dev. Ind. Pharm. 46 (9), 1550–1557. 10.1080/03639045.2020.1811302 Zeng Y. C. Li S. Liu C. Gong T. Sun X. Fu Y. (2017). Soluplus micelles for improving the oral bioavailability of scopoletin and their hypouricemic effect in vivo . Acta Pharmacol. Sin. 38 (3), 424–433. 10.1038/aps.2016.126 Zhang F. Zhang Y. Yang T. Ye Z. Q. Tian J. Fang H. R. (2019). Scopoletin suppresses activation of dendritic cells and pathogenesis of experimental autoimmune encephalomyelitis by inhibiting NF-κB signaling. Front. Pharmacol. 10, 863. 10.3389/fphar.2019.00863 Zhang W. Zhao W. Ge C. Li X. Sun Z. (2021). Scopoletin attenuates intracerebral hemorrhage-induced brain injury and improves neurological performance in rats. Neuroimmunomodulation 28 (2), 74–81. 10.1159/000505731 Zhang W. Y. Lee J. J. Kim Y. Kim I. S. Park J. S. Myung C. S. (2010). Amelioration of insulin resistance by scopoletin in high-glucose-induced, insulin-resistant HepG2 cells. Horm. Metab. Res. 42 (13), 930–935. 10.1055/s-0030-1265219 Zhao Y. X. Wang M. Dong W. T. Li Y. (2019). Pharmacokinetics, bioavailability and metabolism of scopoletin in dog by ultra-high-performance liquid chromatography combined with linear ion trap-Orbitrap tandem mass spectrometry. Biomed. Chromatogr. 33 (3), e4436. 10.1002/bmc.4436 Zhou R. Kan S. Cai S. Sun R. Yuan H. Yu B. (2020). Scopoletin activates adenosine monophosphate-activated protein kinase/mammalian target of rapamycin signaling pathway and improves functional recovery after spinal cord injury in rats. Pharmacology 105 (5-6), 349–359. 10.1159/000503866 Zhu Y. Jiang Z. Liu L. Yang X. Li M. Cheng Y. (2023). Scopoletin reactivates latent HIV-1 by inducing NF-κB expression without global T cell activation. Int. J. Mol. Sci. 24 (16), 12649. 10.3390/ijms241612649 Glossary
AGEs Advanced glycation end products
AUC Area under the curve of the glucose tolerance test
APOA4 Apolipoprotein A-IV
AMPK AMP-activated protein kinase
Aβ Amyloid β
ACC Acetyl-CoA carboxylase
ALT Alanine transaminase
AST Aspartate transaminase
ADAM A disintegrin and metalloproteinases
ACE Angiotensin-converting enzyme
AGII Angiotensin II
AR Aldose reductase
AChE Acetylcholinesterase
CYP Cytochrome P450 isoforms
BuChE Butyrylcholinesterase
BCL-2 B-cell lymphoma 2
BACE1 Aβ-site precursor protein-cleaving enzyme 1
CAT Catalase
COX-2 Cyclooxygenase-2
CREB cAMP response element binding protein
CSF3 Colony-stimulating factor 3
CDKN1A Cyclin-dependent kinase inhibitor 1A
CIDEA Cell death-inducing DFFA-like effector A
COL1A1 Collagen type 1
CPT Carnitine palmitoyltransferase
CYP7A1 Cholesterol 7 alpha-hydroxylase
ERRFI1 ERBB receptor feedback inhibitor 1
DGAT2 Diacylglycerol O-acyltransferase 2
DPPH Diphenyl-2-picrylhydrazyl
DA Dopamine
DBP Diastolic pressure
ERK-1 Extracellular signal-regulated kinases-1
EC 50 Concentration for 50% of maximal effect
FFA Free fatty acid
FOXO Forkhead box O transcription factor
FAS Fatty acid synthase
FGF2 Fibroblast growth factor 2
FoxO Family of mammalian forkhead box O
FtsZ Filamentous temperature sensitive protein Z
GK Glucokinase
G6PD Glucose-6-phosphate dehydrogenase
GLUT4 Glucose transporter 4
GR Glutathione reductase
GSH Glutathione
GABA Gamma-aminobutyric acid
GPX Glutathione peroxidase
GPT Glutamic pyruvic transaminase
GDF-15 Growth differentiation factor 15
HbA1c Glycosylated hemoglobin
H 2 O 2 Hydrogen peroxide
HUVECs Human umbilical vein endothelial cells
HOMA-IR Homeostasis model assessment of insulin resistance
HFFD High-fat high-fructose diet
IFN-γ Interferon-y
IC 50 Half maximal inhibitory concentration
IPGTT Intraperitoneal glucose tolerance test
IL Interleukin
iNOS Nitric oxide synthase
IRS Insulin receptor substrate
LDH Lactic dehydrogenase
LDL Low-density lipoprotein
VLDL Very-low density lipoprotein
LPS Lipopolysaccharide
LHP Lipid hydroperoxide
LTP Long-term potentiation
LTD Long-term depression
MAPK Mitogen-activated protein kinase
MPO Myeloperoxidase
MITF Microphthalmia-associated transcription factor
MDA Malondialdehyde
MABP Mean arterial blood pressure
MMP Matrix metallopeptidase
MCP-1 Monocyte chemoattractant protein-1
MAO Monoamine oxidase
mTOR Mammalian target of rapamycin
MAOs Monoamine oxidases
MyD88 Myeloid differentiation primary response gene 88
MMP-13 Matrix metallopeptidase 13
MIC Minimum inhibitory concentration
NE Norepinephrine
NF-κB Nuclear factor-kappa B
NAG N-acetyl-β-D-glucosaminidase
Nrf2 Nuclear factor-erythroid 2-related factor 2
NFAT Nuclear factor of activated T cells
NQO1 Quinone oxidoreductase
nAChR Nicotinic ACh receptor
OGTT Oral glucose tolerance test
PC Protein carbonyl
PI3K Phosphoinositide 3-kinase
PGE2 Prostaglandin E2
PPARγ Peroxisome proliferator-activated receptor γ
PTP1B Protein tyrosine phosphatase 1B
PAP Phosphatidate phosphohydrolase
PMA Phorbol myristate acetate
PCNA Proliferating cell nuclear antigen
PKC Protein kinase C
PTEN Phosphatase and tensin homolog
ROS Reactive oxygen species
RLAR Rat lens aldose reductase; SD, Sprague‒Dawley
SREBP Sterol regulatory element-binding protein 1C
STZ Streptozotocin
SOD Superoxide dismutase
SDH Sorbitol dehydrogenase
SIRT1 Sirtuin-1
SBP Systolic pressure
SOCS1 Suppressor of cytokine signaling 1
TC Total cholesterol
TG Triglycerides
TBARS Thiobarbituric acid reactive substance
TLR4 Toll-like receptor 4
TNF-α Tumor necrosis factor α
TRIF TIR-domain-containing adapter-inducing interferon-β
TRP53 Protein 53 tumor suppressor
VEGF-A Vascular endothelial growth factor A
WAT White adipose tissue